KOL | Hiroshi FujishimaDepartment of Ophthalmology, Tsurumi University School of Dental Medicine, Kanagawa 230-0063, Japan;, fujishima117@gmail.com | Department of Ophthalmology, Keio University ... |
CV Kol pour Hiroshi Fujishima
| Year | |
|---|---|
| 2021 | Department of Ophthalmology, Tsurumi University School of Dental Medicine, Kanagawa 230-0063, Japan;, Ophthalmology, Tsurumi University Dental Hospital, Yokohama, Kanagawa, Japan |
| 2020 | Department of Ophthalmology, Keio University School of Medicine, Tokyo 160-0016, Japan;, (E.S.);, (N.A.);, (Y.O.) Fujishima Eye Clinic, Niigata 949-6600, Japan |
| 2019 | Department of Ophthalmology, Tsurumi University School of Dental Medicine, Tsurumi-ku 230-8501, Kanagawa, Japan;, (N.K.);, (A.S.);, (H.F.) Tsurumi University School of Dental Medicine, Yokohama, Japan |
| 2016 | Department of Ophthalmology, Tsurumi University Dental Hospital, Kanagawa, Japan |
| 2015 | From the *Department of Ophthalmology, Tsurumi University School of Dental Medicine, Kanagawa; and †Department of Ophthalmology, Tokyo Saiseikai Central Hospital; and ‡J&J Ocular Surface and Visual Optics Department, Keio University School of Medicine, Tokyo, Japan. |
| 2014 | Department of Ophthalmology, Tsurumi University School of Dental Medicine, Yokohama, Japan |
| 2012 | Department of Ophthalmology, Tsurumi University School of Dental Medicine, Kanagawa |
| 2011 | Department of Ophthalmology, Tsurumi University Dental Hospital, Kanagawa, Japan. |
| 2010 | Department of Ophthalmology, International University of Health and Welfare, Mita Hospital, Tokyo, Japan. |
| 2009 | Department of Ophthalmology, Keio University, Tokyo, Japan. |
| 2008 | Department of Ophthalmology, International University of Welfare, Mita Hospital, Tokyo, Japan |
| 2007 | International University of Health and Welfare, Department of Ophthalmology, Mita Hospital, 1-4-3 Mita, Minato-ku, Tokyo 108-8329, Japan. |
| 2006 | From the *Department of Ophthalmology, Tokyo Dental College, Ichikawa General Hospital, Ichikawa, Japan; †Keio University School of Medicine, Tokyo, Japan; and ‡Hara Eye Clinic, Otawara, Tochigi Prefecture, Japan. Department of Ophthalmology, Keio University School of Medicine |
| 2005 | From the Department of Ophthalmology, Keio University, Tokyo, Japan; the Department of Ophthalmology, Tokyo Dental College, Sugano 5-11-13, Ichikawa, Chiba 272-8513, Japan |
| 2004 | From the Departments of *Ophthalmology and †Dermatology, Tokyo Dental College, Ichikawa, Chiba, Japan. Department of Ophthalmology, Keio University, Tokyo, Japan |
| 2003 | Department of Ophthalmology, Tokyo Dental College, Chiba, Japan |
| 2002 | Department of Ophthalmology, Tokyo Dental College, Sugano, Ichikawa, Japan. |
| 2001 | From the Departments of Ophthalmology (N.A-K., K.F., K.T., K.U., H.F.) and Dermatology (S.T.), Tokyo Dental College, Chiba, Japan. |
| 1998 | Department of Ophthalmology, Tokyo Dental College, Ichikawa, Chiba, Japan. |
| 1997 | Department of Ophthalmology, Tokyo Dental College, Chiba |
| 1996 | Department of Ophthalmology, Tokyo Dental College; Department of Ophthalmology, Keio University School of Medicine |
| 1995 | Chiba, Tokyo, and Akita, Japan Department of Ophthalmology Tokyo Dental College, Chiba |
| 1994 | Department of Ophthalmology, School of Medicine, Keio University, Tokyo, Japan. |
Hiroshi Fujishima: Statistiques d'influence
Rapport d'exécution
| Concept | World rank |
|---|---|
| severe akc | #1 |
| fml 002 | #1 |
| eye itching | #1 |
| akc patients | #1 |
| akc treatment | #1 |
| patients allergic conjunctivitis | #1 |
| severe conjunctivitis eyes | #1 |
| 3 months signs | #1 |
| dha western blotting | #1 |
| allergic enzyme | #1 |
| conjunctivitis seasonal | #1 |
| cd3 cd4bearing cells | #1 |
| dscg 005 | #1 |
| epithelium disorders | #1 |
| allergic docosahexaenoic | #1 |
| eotaxin1 production | #1 |
| objective findings conclusions | #1 |
| tears allergic | #1 |
| conjunctivitis japanese | #1 |
| conjunctival fibroblasts | #1 |
| cytokinestimulation pharmacologic intervention | #1 |
| diagnostic accuracy conjunctivitis | #1 |
| vkc akc | #1 |
| efficacy bromfenac sodium | #1 |
| conjunctivitis concomitantly | #1 |
| allergic conjunctivitis drop | #1 |
| fml patients | #1 |
| fumarate dexamethasone | #1 |
| diseases tear | #1 |
| akc methods | #1 |
| therapy levocabastine | #1 |
| itching levocabastine | #1 |
| selected fml | #1 |
| cox2 conjunctival | #1 |
| talymus | #1 |
| akc tear | #1 |
| eyewash solutions | #1 |
| instillation bromfenac | #1 |
| allergens levocabastine | #1 |
| signs palpebral | #1 |
| il4 tear | #1 |
| satisfaction suspensions | #1 |
| keratoconjunctivitis background | #1 |
| binocular conjunctivitis | #1 |
| akc vkc | #1 |
| improvement combinedtreatment | #1 |
| adenovirus capilia | #1 |
| tacrolimus eye treatment | #1 |
| bak epithelium disorders | #1 |
| treatment vernal keratoconjunctivitis | #1 |
| vkc conclusions | #1 |
| fluorometholone 002 | #1 |
| antagonists child conjunctivitis | #1 |
| prostaglandin tears | #1 |
| accuracy conjunctivitis | #1 |
| eyewash solutions bak | #1 |
| il4 causing | #1 |
| eye fml | #1 |
| tacrolimus tears | #1 |
| adverse events scores | #1 |
| pcr eotaxin1 | #1 |
| commercial washing solution | #1 |
| washing allergens | #1 |
| iop akc | #1 |
| sodium allergic | #1 |
| tacrolimus eye | #1 |
| fml dscg | #1 |
| scleritis tacrolimus | #1 |
| patients akc | #1 |
| test capilia | #1 |
| initiation tacrolimus treatment | #1 |
| dscg bf | #1 |
| solution allergic | #1 |
| ketotifen fumarate dexamethasone | #1 |
| epithelial pge2 | #1 |
| conjunctivitis conjunctival | #1 |
| hyperemia pain | #1 |
| conjunctivitis treated | #1 |
| production tranilast | #1 |
| bf concomitantly | #1 |
| incubated interleukin | #1 |
| allergic conjunctivitis efficacy | #1 |
| 0001 allerwatch | #1 |
| akc compared | #1 |
| eyewash | #1 |
| dscg symptoms | #1 |
| allergic tranilast | #1 |
| conjunctivitis including | #1 |
| conjunctivitis aims | #1 |
| immunocytochemical study rtpcr | #1 |
| 01 ophthalmic solution | #1 |
| ded anti | #1 |
| allergic postoperative | #1 |
| cedrus conjunctivitis | #1 |
| patients capilia | #1 |
| 10 objective signs | #1 |
| allerwatch positivity rate | #1 |
| keratoconjunctivitis male | #1 |
| bromfenac sodium treatment | #1 |
| keratocytes tnfα | #1 |
| eye allerwatch | #1 |
| dha il4 | #1 |
| patients severe conjunctivitis | #1 |
| levocabastine artificial | #1 |
| akc | #1 |
| bromfenac sodium bf | #1 |
| rsv conjunctival | #1 |
| severity objective signs | #1 |
| akc vernal | #1 |
| vkc cases | #1 |
| capilia adeno | #1 |
| conjunctivitis helper | #1 |
| eye wash | #1 |
| tacrolimus eye drops | #1 |
| scores hyperemia | #1 |
| bromfenac sodium | #1 |
| inhibition eotaxin1 | #1 |
| efficacy fml | #1 |
| allergic corneal | #1 |
| allerwatch diagnostic accuracy | #1 |
| clinical signs akc | #1 |
| sodium ophthalmic solution | #1 |
| tears conjunctival fibroblasts | #1 |
| radioimmunoassay il4 | #1 |
| production ketotifen fumarate | #1 |
| rate allerwatch | #1 |
| corneal epithelium disorders | #1 |
| tacrolimus eye drop | #1 |
| pge2 human conjunctival | #1 |
| release inhibitor purpose | #1 |
| 12 patients akc | #1 |
| sodium bf | #1 |
| allergenmediated conjunctivitis | #1 |
| samples allergic conjunctivitis | #1 |
| il4 tranilast | #1 |
| conjunctival fibroblasts production | #1 |
| allergic conjunctivitis | #1 |
| concomitant bf | #1 |
| stat6results | #1 |
| compared fluorometholone | #1 |
| allerwatch tests | #1 |
| drops elicited | #1 |
| suppressing pge2 production | #1 |
| tranilast dexamethasone | #1 |
| dscg fml | #1 |
| conjunctivitis enrolled | #1 |
| adeno eye | #1 |
| capilia adeno eye | #1 |
| initiating tacrolimus | #1 |
| atopic keratoconjunctivitis akc | #1 |
| itchy sensation | #1 |
| eyebon | #1 |
| akc administration | #1 |
| artificial tears positive | #1 |
| levocabastine artificial tears | #1 |
| eyebon eye | #1 |
| instillation symptoms | #1 |
| commercial eyewash solutions | #1 |
| bromobenzenes conjunctivitis | #1 |
| patients atopic keratoconjunctivitis | #1 |
| subjective ocular symptoms | #1 |
| eyewash solution bak | #1 |
| production conjunctival fibroblasts | #1 |
| conjunctival cedar | #1 |
| tacrolimus ophthalmic | #1 |
| positivity rate allerwatch | #1 |
| solution ocular | #1 |
| hundredandseventy eyes | #1 |
| bak epithelium | #1 |
| akc allergic | #1 |
| fourgraded severity | #1 |
| atopic keratoconjunctivitis | #1 |
| primary human conjunctival | #1 |
| child conjunctivitis | #1 |
| commercial eyewash | #1 |
| tranilast production | #1 |
| postoperative conjunctivitis | #1 |
| keratoconjunctivitis vernal | #1 |
| conclusions objective assessments | #1 |
| rapid ophthalmic | #1 |
| nsaids systemic control | #1 |
| conjunctivitis scleritis episcleritis | #1 |
| exacerbation vkc | #1 |
| tears allergic patients | #1 |
| suspension treating | #1 |
| 01 tacrolimus eye | #1 |
| eyewash solution | #1 |
| action child conjunctivitis | #1 |
| severe binocular conjunctivitis | #1 |
| systemic control pain | #1 |
| ocular allergic diseases | #1 |
| eotaxin conjunctival fibroblasts | #1 |
| experience 01 | #1 |
| tacrolimus ophthalmic solution | #1 |
| adult cedrus conjunctivitis | #1 |
| tacrolimus ophthalmic suspension | #1 |
| ige allerwatch | #1 |
| higher capilia | #1 |
| tnfalpha tranilast dexamethasone | #1 |
| higher akc | #1 |
| eye surface years | #1 |
| characterized conjunctival | #1 |
| allerwatch higher | #1 |
| fml administered | #1 |
| include conjunctival | #1 |
| drop levocabastine | #1 |
| cases severe conjunctivitis | #1 |
| selective chemotactic effects | #1 |
| tranilast eotaxin1 | #1 |
| vkc april | #1 |
| keratoconjunctivitis akc | #1 |
| bf fml | #1 |
| drop steroid | #2 |
| olopatadine visit | #2 |
| evaluate superiority | #2 |
| conjunctivitis epitheliopathy | #2 |
| 95 adjuvant betamethasone | #2 |
| iop topical steroids | #2 |
| akc levels | #2 |
| oral ari | #2 |
| brush cytology samples | #2 |
| immunoregulatory effects study | #2 |
| epinastine ophthalmic solution | #2 |
| decrease corneal temperature | #2 |
| unpaired ttest talymus | #2 |
| oral ari administration | #2 |
| conjunctiva bulbar | #2 |
| papilla accompanied | #2 |
| steroid metaregression | #2 |
| talymus akc | #2 |
| japan topical tacrolimus | #2 |
| conjunctivitis representative | #2 |
| elasticity severity | #2 |
| sem575 | #2 |
| largescale study protocol | #2 |
| extents corneal | #2 |
| rhodanine rose | #2 |
| factor vkc | #2 |
| conjunctivitis retrospective | #2 |
| adjuvant betamethasone | #2 |
| adjustments epitheliopathy | #2 |
| solutions japan | #2 |
| keratoconjunctivitis corneal | #2 |
| eyes 824 | #2 |
| formation palpebral | #2 |
| production specular | #2 |
| steroids epitheliopathy | #2 |
| fluorescein conjunctival injection | #2 |
| corneal epitheliopathy | #2 |
| severity corneal complications | #2 |
| air pollutants prevalence | #2 |
| severe allergic conjunctivitis | #2 |
| severity corneal damage | #2 |
| sem575 clinical | #2 |
| prevalence akc | #2 |
| conventional antiallergic drugs | #2 |
| recurrence corneal lesions | #2 |
| dryness scores | #2 |
| epitheliopathy shield | #2 |
| control subjects eyes | #2 |
| 1 month tacrolimus | #2 |
| bovine placebo | #2 |
| ecp levels akc | #2 |
| olopatadine cedar | #2 |
| papillae preventing | #2 |
| ketotifen dexamethasone | #2 |
| giant papillary formation | #2 |
| tears akc | #2 |
| detected akc | #2 |
| scores tacrolimus | #2 |
| cedrus conjunctiva | #2 |
| treatment ecp concentrations | #2 |
| papillary formation | #2 |
| ensured proving | #2 |
| score adjustments | #2 |
| akc patients correlation | #2 |
| eyelid skin elasticity | #2 |
| excision cobblestonelike papillae | #2 |
| dermatitis remission | #2 |
| ocular surface mucin | #2 |
| signs blood concentration | #2 |
| study designopen cohort | #2 |
| akc adolescent | #2 |
| allergic diagnosis | #2 |
| cobblestonelike papillae | #2 |
| akc sac patients | #2 |
| sodium ophthalmic | #2 |
| corneal epitheliopathy score | #2 |
| 2helper cell | #2 |
| lid skin | #2 |
| mucin analyzed | #2 |
| elevation tacrolimus | #2 |
| refractory allergic | #2 |
| disease antiallergic | #2 |
| keratoconjunctivitis age | #2 |
| baseline papillae | #2 |
| akc 6 | #2 |
| scores papillary | #2 |
| papillae mucous discharge | #2 |
| simple papillary resection | #2 |
| premedication combined | #2 |
| edema height | #2 |
| tears thiazolidines | #2 |
| month eyewash | #2 |
| edema corneal damage | #2 |
| methods thirtysix patients | #2 |
| epinastine superiority | #2 |
| superiority epinastine | #2 |
| conjunctivitis adolescent | #2 |
| asthma heart diseases | #2 |
| conclusions bromfenac | #2 |
| metaregression analysis glaucoma | #2 |
| corneal recurrences | #2 |
| administered elf | #2 |
| tear ige correlation | #2 |
| akc 1 | #2 |
| drops conjunctival | #2 |
| complain foreign | #2 |
| administered elf bovine | #2 |
| accompanied subjective | #2 |
| adjustments epitheliopathy score | #2 |
| eyelid atopic dermatitis | #2 |
| effects tacrolimus | #2 |
| treatment shield ulcer | #2 |
| tarsal brush | #2 |
| tacrolimus 1 month | #2 |
| representative subjective | #2 |
| eosinophils corneal damage | #2 |
| formation akc | #2 |
| epitheliopathy refractory | #2 |
| hyperemia lacrimation | #2 |
| olopatadine ocular | #2 |
| sem575 quantitatively | #2 |
| mucous discharge severity | #2 |
| diathesis subjective | #2 |
| folliculosis papillae | #2 |
| pollutants prevalence | #2 |
| corneal lesions | #2 |
| corneal complications height | #2 |
| allergic endophthalmitis | #2 |
| conjunctiva atopic | #2 |
| effects topical tacrolimus | #2 |
| mmc aided | #2 |
| papillae akc | #2 |
| akc allergic diagnosis | #2 |
| signs decreased | #2 |
| regrowth 7 eyes | #2 |
| giant papillae formation | #2 |
| 062 tear | #2 |
| ulcer complain | #2 |
| cornea grading | #2 |
| based papillae | #2 |
| period rhodanine | #2 |
| tacrolimus iop | #2 |
| plaques 791 | #2 |
| treated bromfenac | #2 |
| ecp severity markers | #2 |
| akc 10 eyes | #2 |
| severity eyelid | #2 |
| severity corneal lesions | #2 |
| serum allergic parameters | #2 |
| tacrolimus tonometry | #2 |
| cac test | #2 |
| height papillae | #2 |
| japan akc | #2 |
| muc16 immunohistochemistry | #2 |
| epitheliopathy score | #2 |
| sodium bromfenac | #2 |
| efficacy severe akc | #2 |
| mmc 7 eyes | #2 |
| eyelid elasticity | #2 |
| nonwash | #2 |
| akc adult | #2 |
| lesions allergic | #2 |
| correlation eosinophils | #2 |
| test papillae | #2 |
| reported eotaxin | #2 |
| simple resection regrowth | #2 |
| blepharitis ceramides | #2 |
| conjunctival injection reduction | #2 |
| suspension lactoferrin | #2 |
| neutrophils brush | #2 |
| benzophenones bromobenzenes | #2 |
| adjuvant fluorometholone 95 | #2 |
| ophthalmic nsaid | #2 |
| tear film layer | #2 |
| corneal ulcers patients | #2 |
| papillae limbus | #2 |
| adjuvant fluorometholone | #2 |
| neutrophils corneal damage | #2 |
| total clinical signs | #2 |
| correlation neutrophils | #2 |
| papillary excision | #2 |
| atopic diagnostic techniques | #2 |
| elasticity eyelid | #2 |
| seasonal allergic conjunctivitis | #2 |
| allergy accompanied | #2 |
| improvement vital staining | #2 |
| epinastine 15 minutes | #2 |
| patients shield ulcers | #2 |
| akc 10 | #2 |
| papillae severe | #2 |
| corneal lesions regrowth | #2 |
| tacrolimus published data | #2 |
| objective signs baseline | #2 |
| shield ulcers patients | #2 |
| drops hyperemia | #2 |
| akc young adult | #2 |
| skin elasticity patients | #2 |
| resolution thermography | #2 |
| suspension talymus | #2 |
| 18 akc | #2 |
| patients shield | #2 |
| brush cytology patients | #2 |
| csa akc | #2 |
| aureussecreted enterotoxins | #2 |
| akc treated | #2 |
| drop concomitantly | #2 |
| tacrolimus detection limit | #2 |
| ceramide gel application | #2 |
| bromfenac effective | #2 |
| betamethasone glaucoma | #2 |
| patients tacrolimus eye | #2 |
| lower conjunctival sacs | #2 |
| lessen steroid | #2 |
| regrowth papillae | #2 |
| inflammatory child child | #2 |
| conjunctivitis 10 | #2 |
| treatment total signs | #2 |
| bromfenac sodium bromfenac | #2 |
| tacrolimus 12 weeks | #2 |
| allergic conjunctivitis levocabastine | #2 |
| tacrolimus shield | #2 |
| vkc atopic keratoconjunctivitis | #2 |
| ari ocular | #2 |
| correlation fluorescein | #2 |
| atopic blepharitis | #2 |
| swelling folliculosis | #2 |
| conjunctivitis purpose | #2 |
| corneal epithelial signs | #2 |
| diabetic patients ono2235 | #2 |
| recurrence corneal complications | #2 |
| limbal swelling | #2 |
| conjunctivitis condition | #2 |
| treatment atopic blepharitis | #2 |
| sac healthy | #2 |
| eyes betamethasone | #2 |
| allergic conjunctivitis akc | #2 |
| placebo noninferiority | #2 |
| solution epinastine | #2 |
| pge2 tears | #2 |
| excision cobblestone | #2 |
| noninferiority olopatadine | #2 |
| concomitantly abovementioned | #2 |
| administration specular | #2 |
| conjunctival injection edema | #2 |
| aided papillary | #2 |
| including akc | #2 |
| nonpreserved eyewash solution | #2 |
| japan topical | #2 |
| cutometer sem575 | #2 |
| tacrolimus lessen | #2 |
| oral ari ono2235 | #2 |
| conjunctiva papillary | #2 |
| normal blinking patients | #2 |
| defined conjunctival | #2 |
| epitheliopathy corneal | #2 |
| environmental studies prevalence | #2 |
| patients corneal ulcers | #2 |
| eyewash 005 | #2 |
| bromfenac ophthalmic solution | #2 |
| post cataract surgery | #2 |
| patients severe akc | #2 |
| selected bf | #2 |
| female humans akc | #2 |
| corneal findings | #2 |
| eyelid atopic | #2 |
| corneal damage height | #2 |
| corneal damage patients | #2 |
| improvement corneal fluorescein | #2 |
| corneal temperature patients | #2 |
| conjunctivitis proliferative | #2 |
| tacrolimus topical | #2 |
| topical antiallergic agents | #2 |
| conjunctival findings severity | #2 |
| epitheliopathy steroids | #2 |
| topical tacrolimus combination | #2 |
| total signs symptoms | #2 |
| 001 brush | #2 |
| deqs tear | #2 |
| treatment tear | #2 |
| cytodiagnosis dermatitis | #2 |
| diagnosis ensured | #2 |
| conjunctival corneal cells | #2 |
| oral aldose | #2 |
| proliferative called | #2 |
| tacrolimus detection | #2 |
| vkc japan | #2 |
| vkc 5 | #2 |
| akc aureus | #2 |
| endpoint itching scale | #2 |
| epitheliopathy patients | #2 |
| score topical | #2 |
| drops refractory | #2 |
| bovine entericcoated lactoferrin | #2 |
| lacrimation objective | #2 |
| allergic conjunctivitis ige | #2 |
| lactoferrin 01 | #2 |
| conjunctiva conjunctivitis allergic | #2 |
| akc dyes humans | #3 |
| eye washing | #3 |
| laser cellflaremetry | #3 |
| allergic corneal ulcer | #3 |
| histamine cedar pollen | #3 |
| postsurgical conjunctivitis | #3 |
| akc higher muc1 | #3 |
| superficial cells conjunctiva | #3 |
| papillary resection | #3 |
| ocular surface diabetes | #3 |
| conjunctivitis pm25 | #3 |
| vkc exacerbation | #3 |
| production conjunctival | #3 |
| samples correlate | #3 |
| conjunctival fibroblasts tryptase | #3 |
| surgery dfna | #3 |
| papillae morphometric | #3 |
| akc rose bengal | #3 |
| vkc papillae | #3 |
| eyes vkc | #3 |
| cooling cataract | #3 |
| pollen august | #3 |
| diseases acds | #3 |
| vkc cell | #3 |
| traumatic swelling | #3 |
| conjunctivitis lymphocytes | #3 |
| akc periostin | #3 |
| 1 month initiation | #3 |
| child conjunctiva | #3 |
| papillae upper | #3 |
| aged elisa | #3 |
| antieaigg | #3 |
| conjunctival fibroblasts rtpcr | #3 |
| severe allergy patients | #3 |
| improvement squamous metaplasia | #3 |
| 5ac brush | #3 |
| insufficient tear | #3 |
| periostin comorbidities | #3 |
| signs remission | #3 |
| formation vernal | #3 |
| portable recordable | #3 |
| histamine specimens | #3 |
| adedry eye | #3 |
| 21 akc patients | #3 |
| superior limbic portion | #3 |
| technique 2 eyes | #3 |
| vkc fibronectin | #3 |
| lower muc5ac | #3 |
| vivo corneal akc | #3 |
| 111 177 | #3 |
| giant papilla | #3 |
| ophthalmic solution nsaid | #3 |
| healing allergic | #3 |
| conjunctivitis allergic | #3 |
| formation vkc | #3 |
| nbs normal eyes | #3 |
| sensitivity tear | #3 |
| normal controls collagens | #3 |
| dfna eye dfna | #3 |
| mmc excision | #3 |
| dramatic healing | #3 |
| drop selected | #3 |
| commercial washing | #3 |
| autumnal pollen | #3 |
| il1beta th2 cytokines | #3 |
| vkc eyes | #3 |
| interleukin4 histamine | #3 |
| tryptase conjunctiva | #3 |
| drops treat | #3 |
| measurements schirmer | #3 |
| histamine conjunctival cells | #3 |
| glaucoma amniotic | #3 |
| patients pilocarpine tablets | #3 |
| fibronectin vkc | #3 |
| diclofenac eye drops | #3 |
| temperature evaluate | #3 |
| tear periostin comorbidities | #3 |
| tissue remodeling exacerbation | #3 |
| cytology impression | #3 |
| evaluate tear | #3 |
| akc tear periostin | #3 |
| laser flarecellmetry | #3 |
| 13 eyes 69 | #3 |
| oct graticule | #3 |
| cases vernal | #3 |
| fluorescein glycyrrhizic | #3 |
| akc higher | #3 |
| hyperemia allergic | #3 |
| cholinergic treatment response | #3 |
| conjunctival disease | #3 |
| allergic conjunctivitis aged | #3 |
| pilocarpine visante | #3 |
| cases vkc | #3 |
| akc confocal microscopy | #3 |
| rtpcr par2 | #3 |
| dibenzoxepins female | #3 |
| strip meniscometry testing | #3 |
| scale tmh | #3 |
| mmcaided papillary resection | #3 |
| dfna control | #3 |
| prospectively diclofenac | #3 |
| tmh measurement | #3 |
| existence par2 | #3 |
| nbs subbasal | #3 |
| underwent staining | #3 |
| antiallergic eye drop | #3 |
| 01 bromfenac | #3 |
| 3 sjögrens syndrome | #3 |
| akc biomarkers | #3 |
| study cutometer | #3 |
| tear periostin | #3 |
| higher muc1 eyes | #3 |
| eye cooling | #3 |
| il1beta th2 | #3 |
| allergic postsurgical | #3 |
| corneal ulceration role | #3 |
| association outpatient attendance | #3 |
| fibers lnfs | #3 |
| sdedry eye | #3 |
| proving type | #3 |
| tear il13 | #3 |
| epinastine placebo | #3 |
| scored global | #3 |
| permeability postoperatively | #3 |
| induced inflammation lenses | #3 |
| vkc sac | #3 |
| ari corneal | #3 |
| 5 eyes akc | #3 |
| ulcers eyes | #3 |
| metry dfna | #3 |
| ulcer akc | #3 |
| conjunctivitis negative | #3 |
| icecold eye mask | #3 |
| prophylaxis conjunctival | #3 |
| increased comfort | #3 |
| aged biological dressings | #3 |
| 01 ophthalmic | #3 |
| aureus akc patients | #3 |
| ebv ade | #3 |
| diabetic corneal disease | #3 |
| central corneal temperature | #3 |
| eosinophils corneal | #3 |
| sde controls | #3 |
| akc atopic dermatitis | #3 |
| pm25 outpatient attendance | #3 |
| insufficient tear supply | #3 |
| histamine cedar | #3 |
| muc1 brush cytology | #3 |
| phenomena tacrolimus | #3 |
| erosions refractory | #3 |
| protein conjunctival fibroblasts | #3 |
| eyes akc | #3 |
| antibody titers ade | #3 |
| patients tmh measurements | #3 |
| sligkv examined | #3 |
| ecp severity | #3 |
| tryptase increases | #3 |
| solutions prospective | #3 |
| insensible administration insensible | #3 |
| treatment oral pilocarpine | #3 |
| allergic cornea | #3 |
| treatment skin elasticity | #3 |
| vkc levels | #3 |
| relevant factor exacerbation | #3 |
| existence par2 mrna | #3 |
| benzamidine par2 | #3 |
| dfna diclofenac epithelium | #3 |
| uncontrollable glaucoma trabeculectomy | #3 |
| efficacy bromfenac | #3 |
| vkc differences | #3 |
| treatment strip meniscometry | #3 |
| cornea atopic | #3 |
| vkc long | #3 |
| conjunctivitis benzamidines | #3 |
| underwent periodic | #3 |
| operation eye | #3 |
| ulcer persistent | #3 |
| membrane uncontrollable | #3 |
| techniques conjunctivitis | #3 |
| lnfs nbs | #3 |
| severe allergic patients | #3 |
| titers ade | #3 |
| corneal akc | #3 |
| nuclei vkc | #3 |
| vkc 5 eyes | #3 |
| 005 mmc | #3 |
| par2 benzamidines blotting | #3 |
| cells brush cytology | #3 |
| alterations tear | #3 |
| injections keratoconjunctivitis | #3 |
| outpatient attendance july | #3 |
| lamp device | #3 |
| july pm25 | #3 |
| pretreatment docosahexaenoic acid | #3 |
| macroerosions | #3 |
| 5ac mrna | #3 |
| 21 akc | #3 |
| corneal complications1 | #3 |
| weekly average values | #3 |
| papillary regrowth | #3 |
| akc alterations | #3 |
| topical cyclosporine 01 | #3 |
| treatment vernal | #3 |
| ssdry | #3 |
| dry eye eye | #3 |
| eyes allergic | #3 |
| oct tmh | #3 |
| 005 collagens | #3 |
| histamine superficial cells | #3 |
| cell flare count | #3 |
| allergic corneal diseases | #3 |
| diclofenac epithelium | #3 |
| cell metry | #3 |
| keratoconjunctivitis leupeptins | #3 |
| 12 akc patients | #3 |
| conjunctiva allergic | #3 |
| tears treatment | #3 |
| dfna eye | #3 |
| akc persistent | #3 |
| pm25 allergic | #3 |
| immunosuppressive eye | #3 |
| differences dfna | #3 |
| technique uncontrollable | #3 |
| lacrimal punctal occlusion | #3 |
| 12 akc | #3 |
| periostin akc | #3 |
| tear periostin patients | #3 |
| techniques tears | #3 |
| ulcers plaques | #3 |
| healed amniotic | #3 |
| corneal epithelial structure | #3 |
| akc confocal | #3 |
| periostin topical | #3 |
| rose bengal akc | #3 |
| superior keratoconjunctiva | #3 |
| healing dramatic healing | #3 |
| flare metry | #3 |
| fluorescein scale | #3 |
| local tear deficiency | #3 |
| ophthalmic solution placebo | #3 |
| par2 cultured | #3 |
| mmc authors | #3 |
| tears adolescent | #3 |
| allerwatch | #3 |
| elisa histamine | #3 |
| treatment atopic keratoconjunctivitis | #3 |
| epithelium adverse | #3 |
| uncontrollable glaucoma | #3 |
| nonpreserved artificial tears | #3 |
| allergic patients conjunctivitis | #3 |
| hydrochloride 01 | #3 |
| interleukin4 tacrolimus | #3 |
| 005 ophthalmic solution | #3 |
| eyes control subjects | #3 |
| patching patient | #3 |
| pollen postoperative | #3 |
| outpatient visits july | #3 |
| akc serum periostin | #3 |
| patching case | #3 |
| akc comorbidities | #3 |
| tear periostin biomarker | #3 |
| conjunctiva conjunctivitis | #3 |
| infrared radiation thermography | #3 |
| reaction conjunctiva | #3 |
| decline corneal | #3 |
| akc eyes | #3 |
| outpatient visits august | #3 |
| conjunctival corneal | #3 |
| inflammation mmc | #3 |
| fibronectin normal controls | #3 |
| vkc relevant factor | #3 |
| dscg administration | #3 |
| thermography evaluate | #3 |
| cultured tryptase | #3 |
| keratoconjunctivitis vkc | #3 |
| 22 eyes 100 | #3 |
| staining muc | #4 |
| muc16 muc5ac alterations | #4 |
| proteinchip array elisa | #4 |
| p0001 brush | #4 |
| cultured conjunctival | #4 |
| ophthalmologists eye drops | #4 |
| allergic fibroblasts | #4 |
| disease akc | #4 |
| controls brush cytology | #4 |
| greater 3 grade | #4 |
| 020 013 | #4 |
| erosion shield | #4 |
| pgd2dependent migration | #4 |
| months papillary | #4 |
| allergic cytological | #4 |
| eye sjögrens syndrome | #4 |
| muc5ac brush | #4 |
| p0001 impression | #4 |
| metaplasia reduction | #4 |
| conjunctivitis vkc | #4 |
| ocular allergic disease | #4 |
| sterilized asian dust | #4 |
| rsv allergic reaction | #4 |
| patients severe vkc | #4 |
| akc sac | #4 |
| fva treatment | #4 |
| topical oral steroids | #4 |
| studied corneal | #4 |
| metaregression analysis effects | #4 |
| grade dry eye | #4 |
| corneal sensitivity measurements | #4 |
| limbal grafts | #4 |
| topical 01 tacrolimus | #4 |
| cytology goblet | #4 |
| papillae giant | #4 |
| lower tear clearance | #4 |
| cells lnfs | #4 |
| conjunctiva allergic conjunctivitis | #4 |
| infected conjunctival | #4 |
| diseases portable | #4 |
| epithelial muc16 | #4 |
| allergic patients elisa | #4 |
| tears pathogenesis | #4 |
| sensitization asian dust | #4 |
| highrisk glaucoma patients | #4 |
| rejection limbal | #4 |
| 2010 allergic | #4 |
| muc1 2 | #4 |
| crth2 peripheral | #4 |
| sterilized asian | #4 |
| moisture checker | #4 |
| acuity akc | #4 |
| simple resection | #4 |
| tears 10 patients | #4 |
| goblet cell muc5ac | #4 |
| muc16 goblet | #4 |
| muc5ac brush cytology | #4 |
| akcaffected patients | #4 |
| tear temperature | #4 |
| keratoconjunctivitis purpose | #4 |
| corneal safety | #4 |
| severe ocular allergies | #4 |
| pgd2 normal volunteers | #4 |
| tear function test | #4 |
| 3004 respondents | #4 |
| vkc normal controls | #4 |
| conjunctival proliferative | #4 |
| 34 15 seconds | #4 |
| epithelial cells rsv | #4 |
| steroids fluorometholone | #4 |
| specimens underwent | #4 |
| performed tears | #4 |
| diameter allergen | #4 |
| histamine h1 antagonist | #4 |
| completely severe | #4 |
| untreated asian dust | #4 |
| healthy individuals rtpcr | #4 |
| solutions piperidines | #4 |
| lesions regrowth | #4 |
| eye wash solution | #4 |
| chemotaxis conjunctiva | #4 |
| interferometry lipids | #4 |
| ige conjunctival | #4 |
| 0001 brush | #4 |
| sac grade | #4 |
| tomography tear | #4 |
| ulcers mucin | #4 |
| ari ono2235 | #4 |
| tablets tears | #4 |
| controls interferometry grade | #4 |
| vmr 3 months | #4 |
| eyes akc patients | #4 |
| corneal ulcers eyes | #4 |
| allergic conjunctivitis prostaglandin | #4 |
| epithelial disease patients | #4 |
| exponential equation inclination | #4 |
| vkc 4 | #4 |
| samples immunocytochemical | #4 |
| corneal temperature eye | #4 |
| adolescent betamethasone | #4 |
| membrane patching | #4 |
| ocular surface epithelial | #4 |
| staining ocular | #4 |
| mucin mucins tears | #4 |
| folliculosis | #4 |
| mucins tears mucin | #4 |
| placebo ophthalmic | #4 |
| rose bengal scores | #4 |
| excision papillary | #4 |
| hypersensitivity mucin | #4 |
| ded 1 | #4 |
| 4 chemokines stimulation | #4 |
| vkc male receptors | #4 |
| eyes sac | #4 |
| oedema papillary | #4 |
| atopic vernal | #4 |
| eyes corneal ulcers | #4 |
| interferometry controls | #4 |
| conjunctivitis methods | #4 |
| tnfalpha30ng | #4 |
| dscg day | #4 |
| photophobia diagnosis | #4 |
| asian dust extract | #4 |
| corneal temperature blink | #4 |
| akc healthy | #4 |
| stimulation chemokine expression | #4 |
| allergic rhinoconjunctivitis allergic | #4 |
| aged rose | #4 |
| acds ophthalmologists | #4 |
| scores conjunctival | #4 |
| genes conjunctival | #4 |
| atopic ocular | #4 |
| atopic dermatitis remission | #4 |
| individuals pgd2 | #4 |
| sio2 20 | #4 |
| muc5ac alterations | #4 |
| acds conventional | #4 |
| dust wheal | #4 |
| levocabastine ophthalmic | #4 |
| thinoptx intraocular | #4 |
| staining muc16 | #4 |
| patient eyes fluorescein | #4 |
| surface conjunctival | #4 |
| treatment vmr values | #4 |
| papillae normal | #4 |
| akc chemotaxis | #4 |
| ophthalmologists evaluated | #4 |
| thermometer 20 | #4 |
| atopic ocular allergies | #4 |
| eosinophil toxic activity | #4 |
| conjunctiva differences | #4 |
| samples histocytological | #4 |
| conventional portable | #4 |
| cornea grading scale | #4 |
| bromfenac ophthalmic | #4 |
| cytometry mild | #4 |
| implantation rollable | #4 |
| controls interferometry | #4 |
| eotaxin1 rantes | #4 |
| steroids iop | #4 |
| thermography anterior | #4 |
| eyes epithelial disease | #4 |
| rsv conjunctiva conjunctivitis | #4 |
| treatment vmr | #4 |
| primary sources chemokines | #4 |
| noninfectious necrotizing | #4 |
| interferometry 2 | #4 |
| greater concentrations tears | #4 |
| deqs scores | #4 |
| allergies blinding | #4 |
| epithelial disease eyes | #4 |
| eyes insignificant | #4 |
| thinoptx | #4 |
| assay pgd2 | #4 |
| eyes video | #4 |
| akc crth2 | #4 |
| surface muc5ac | #4 |
| thinoptx lens | #4 |
| implantation thinoptx | #4 |
| akc crth2 expression | #4 |
| epithelial pge2 production | #4 |
| wilcoxon signed test | #4 |
| underwent corneal | #4 |
| mucins 1 | #4 |
| eye operation | #4 |
| ulcers control subjects | #4 |
| conjunctiva density | #4 |
| samples allergic | #4 |
| clinical conjunctival | #4 |
| level conjunctiva | #4 |
| conjunctivitis levels | #4 |
| chemokine genes fibroblasts | #4 |
| corneal sensitivity measurement | #4 |
| allergic conjunctivitis rsv | #4 |
| fungi epidemiologic studies | #4 |
| insignificant epithelial | #4 |
| persistent 6 | #4 |
| allergic conjunctival | #4 |
| thinoptx acrysof | #4 |
| blinding purpose | #4 |
| temperature corneal | #4 |
| immunologic receptors akc | #4 |
| cytometry mild cases | #4 |
| muc5ac mrna expression | #4 |
| formation conjunctivitis | #4 |
| tryptase dose | #4 |
| trantas | #4 |
| cell muc5ac | #4 |
| eosinophils receptor crth2 | #4 |
| cases sufficient examination | #4 |
| include ocular | #4 |
| defensins greater | #4 |
| defensins conjunctivitis | #4 |
| giemsas staining | #4 |
| vkc conjunctiva conjunctivitis | #4 |
| pathogenesis noninfectious | #4 |
| 10 seconds temperature | #4 |
| epinastine hydrochloride | #4 |
| keratoconjunctivitis lacrimal | #4 |
| portable slit | #4 |
| july pollen | #4 |
| 061 028 degree | #4 |
| levocabastine h1 | #4 |
| akc pgd2dependent migration | #4 |
| pcr epithelial | #4 |
| eyes ulcers | #4 |
| tacrolimus conclusions | #4 |
| recordable slit | #4 |
| fibroblasts primary sources | #4 |
| special brush | #4 |
| male ophthalmic | #4 |
| interleukin2 tears | #4 |
| lower tear function | #4 |
| hydrochloride ophthalmic | #4 |
| conjunctivitis ige | #4 |
| allergic conjunctival diseases | #4 |
| patients topical cyclosporine | #4 |
| akc rtpcr | #4 |
| compared vkc | #4 |
| interferometry grade | #4 |
| weeks vital | #4 |
| corneal ulcers muc5ac | #4 |
| insignificant epithelial disease | #4 |
| par2 mrna protein | #4 |
| ulcers atopic | #4 |
| 33 chemokines | #4 |
| vkc messenger reverse | #4 |
| correlation outpatient | #4 |
| subjects muc5ac | #4 |
| rsv conjunctival epithelium | #4 |
| 18 akc patients | #4 |
| epithelial muc | #4 |
| allergic conjunctival disease | #4 |
| bengal sensation | #4 |
| tears patients | #4 |
| sac control eyes | #4 |
| il4 tears | #4 |
| microscope evaluating | #4 |
| conjunctival papillary | #4 |
| sensation tears | #4 |
| akc immunologic receptors | #4 |
| atopic keratoconjunctivitis purpose | #4 |
| inflammation akc | #4 |
| alterations atopic | #4 |
| tear function patients | #4 |
| bromfenac eye drops | #4 |
| 2 4 alterations | #4 |
| allergic epidemiologic studies | #4 |
| crth2 akc | #4 |
| rsv conjunctiva | #4 |
| eyes thinoptx | #4 |
| patients epithelial disease | #4 |
| patient atopic keratoconjunctivitis | #4 |
| drop artificial tears | #4 |
| severe vkc patients | #4 |
| pgd2dependent migration eosinophils | #4 |
| akc healthy individuals | #4 |
| allergic conjunctivitis patients | #5 |
| intraoperative mitomycin excision | #5 |
| lesion corneal | #5 |
| akc normal subjects | #5 |
| pretreatment dha | #5 |
| younger age effects | #5 |
| allergic cyclosporine | #5 |
| month tear | #5 |
| 005 schirmer1 | #5 |
| topical cyclosporine therapy | #5 |
| bengal suture | #5 |
| cornea cytodiagnosis | #5 |
| fibroblasts fibroblast damage | #5 |
| vkc iop | #5 |
| akc disease | #5 |
| akc hel | #5 |
| supernatants conjunctival | #5 |
| stained conjunctival | #5 |
| adolescent conjunctivitis | #5 |
| vcam1 fibroblasts | #5 |
| il4 histamine | #5 |
| hel akc | #5 |
| warmer applied | #5 |
| meniscus punctal | #5 |
| simple papillary | #5 |
| schiff immunohistochemical | #5 |
| human conjunctival fibroblasts | #5 |
| staining muc5ac | #5 |
| akc laser | #5 |
| antifungal mcfg | #5 |
| wilcoxonmatched pair test | #5 |
| eosinophils activated fibroblasts | #5 |
| allergic keratopathy | #5 |
| 7 conjunctival | #5 |
| eosinophil adherence fibroblasts | #5 |
| corneal involvement | #5 |
| regulation allergic cornea | #5 |
| akc acinar | #5 |
| crth2 eosinophils | #5 |
| controls ebv | #5 |
| hel cytokines | #5 |
| 17 mgd patients | #5 |
| upper palpebral | #5 |
| staining administration | #5 |
| thinoptx iol | #5 |
| 20 sio2 | #5 |
| 15 minutes dose | #5 |
| conjunctival lipid | #5 |
| scans akc | #5 |
| damage impression | #5 |
| tears received | #5 |
| diclofenac eye | #5 |
| months amniotic | #5 |
| bromobenzenes cornea | #5 |
| 20 akc patients | #5 |
| akc patients study | #5 |
| allergic conjunctiva conjunctivitis | #5 |
| 310±165 years | #5 |
| conventional steroid treatment | #5 |
| severe stevensjohnson syndrome | #5 |
| schirmer1 test groups | #5 |
| dryeye symptoms treatment | #5 |
| lipid oxidation hel | #5 |
| ocular anesthesia | #5 |
| 01 mcfg | #5 |
| 5 females akc | #5 |
| vkc atopic | #5 |
| corneal fibroblasts icam1 | #5 |
| 0001 strip | #5 |
| local tear | #5 |
| conjunctival confocal microscopy | #5 |
| severe conjunctivitis | #5 |
| 376±56 years | #5 |
| conjunctiva dermatitis | #5 |
| measurements strip | #5 |
| alpha allergic | #5 |
| ocular allergic | #5 |
| equipment dry | #5 |
| labeling surface akc | #5 |
| 3 cases followup | #5 |
| hel ihc | #5 |
| punctal occlusion oct | #5 |
| inflammation mitomycin | #5 |
| case corneal ulcer | #5 |
| prostaglandin chemotaxis | #5 |
| pgd2 normal | #5 |
| crth2 prostaglandin receptors | #5 |
| eye circulating | #5 |
| solution olopatadine | #5 |
| stainings tear | #5 |
| accompanied varying | #5 |
| treatment shield | #5 |
| conjunctivitis pollen | #5 |
| study epinastine | #5 |
| females akc | #5 |
| cornea explain | #5 |
| array chemotaxis | #5 |
| tnfα costimulation | #5 |
| scores expressibility | #5 |
| trantas dots | #5 |
| histamine superficial | #5 |
| inflammatory cells hel | #5 |
| disposable eyelid | #5 |
| accompanying allergic | #5 |
| injection conjunctival | #5 |
| age 9 ± | #5 |
| akc ecp | #5 |
| ihc conjunctival inflammation | #5 |
| anterior scleritis patients | #5 |
| thiazolidines administration | #5 |
| visits july | #5 |
| adhered corneal | #5 |
| conjunctival allergen | #5 |
| asthenopia dry | #5 |
| conjunctiva mmc | #5 |
| stimulated conjunctival | #5 |
| impression brush | #5 |
| postsurgical inflammation | #5 |
| situ nickend regulation | #5 |
| ophthalmic suspension | #5 |
| dryeye symptoms | #5 |
| hne ihc | #5 |
| ocular surface disorder | #5 |
| damaged eosinophil | #5 |
| treatment tacrolimus ointment | #5 |
| fibroblasts eosinophil adherence | #5 |
| pm25 outpatient | #5 |
| mitomycin excision | #5 |
| ophthalmic test | #5 |
| keratoconjunctivitis giant | #5 |
| mcfg eye | #5 |
| impression cytology samples | #5 |
| warmer improved | #5 |
| solutions pollen | #5 |
| conjunctivitis prostaglandin | #5 |
| severity akc | #5 |
| cytokinestimulation | #5 |
| layer mgd | #5 |
| signs akc | #5 |
| controls inflammatory cells | #5 |
| treatment epinastine | #5 |
| ulcer dermatitis | #5 |
| disposable eyelidwarming device | #5 |
| conjunctival inflammatory status | #5 |
| worse akc | #5 |
| endophthalmitis eosinophils | #5 |
| anterior fluorometry | #5 |
| oct lower | #5 |
| ulcers controls | #5 |
| allergic drug therapy | #5 |
| eye warmer treatment | #5 |
| 329±57 years | #5 |
| treatment dryeye symptoms | #5 |
| allergic female | #5 |
| visits august | #5 |
| disease conjunctivitis | #5 |
| cells vkc | #5 |
| eosinophils immunologic receptors | #5 |
| lower atopic | #5 |
| cases tests | #5 |
| temperature blink | #5 |
| eosinophil adhesion fibroblasts | #5 |
| diseases required | #5 |
| alterations ocular | #5 |
| eye warmer | #5 |
| samples akc | #5 |
| status confocal | #5 |
| keratoconjunctivitis objective | #5 |
| allergic conjunctivitis cac | #6 |
| bengal vital stainings | #6 |
| eosinophils crth2 | #6 |
| ointment blood | #6 |
| findings dry eye | #6 |
| treatment tacrolimus | #6 |
| dermatitis scored | #6 |
| pathogenesis ocular | #6 |
| tears xerophthalmia | #6 |
| hyperemia imidazoles | #6 |
| examinations tear | #6 |
| dressings female | #6 |
| scores goblet | #6 |
| elevation refractory | #6 |
| akc vernal keratoconjunctivitis | #6 |
| tear stability values | #6 |
| conjunctival confocal | #6 |
| upper tarsal conjunctiva | #6 |
| instability conjunctival | #6 |
| atopic eyelids | #6 |
| schirmer1 test values | #6 |
| topical levocabastine | #6 |
| tbut vital | #6 |
| conjunctival brush cytology | #6 |
| allergens cedrus | #6 |
| topical cys treatment | #6 |
| 20 pbs | #6 |
| rtpcr epithelial cells | #6 |
| ade sde | #6 |
| challenge cac | #6 |
| coated elf | #6 |
| female fluorometholone | #6 |
| papillae mucous | #6 |
| ecp markers | #6 |
| tacrolimus chronic | #6 |
| induced tear | #6 |
| solution commercial | #6 |
| concomitant eye | #6 |
| topical cys | #6 |
| allergic diathesis | #6 |
| samples underwent | #6 |
| cgvhd improvements | #6 |
| conjunctivitis sac | #6 |
| functions topical | #6 |
| il4 il2r | #6 |
| regulation benzamidines | #6 |
| noninvasive suction device | #6 |
| fluorometholone follow | #6 |
| 4 muc | #6 |
| corneal temperature | #6 |
| syndrome tablets | #6 |
| severe vernal | #6 |
| defect ped | #6 |
| fibroblasts conjunctival | #6 |
| eyes atopic | #6 |
| conjunctival diseases | #6 |
| tears acinar | #6 |
| tear ecp | #6 |
| ocular fatigue | #6 |
| differences tear | #6 |
| patients seldi | #6 |
| controlling eyelid | #6 |
| density conjunctival | #6 |
| evaporation vital | #6 |
| specimens akc | #6 |
| grading tear | #6 |
| oxidation hel | #6 |
| pcr muc5ac | #6 |
| corneal damage | #6 |
| eosinophil recruiting chemokines | #6 |
| cyclosporine 01 | #6 |
| ocular surface findings | #6 |
| defect penetrating | #6 |
| dfna | #6 |
| intolerable irritation | #6 |
| testing tear | #6 |
| levels air pollutants | #6 |
| severe stevens | #6 |
| extract sterilized | #6 |
| rose bengal dyes | #6 |
| rate tbut | #6 |
| treatment postoperative inflammation | #6 |
| patients visante | #6 |
| itching conjunctival | #6 |
| eye evaluated | #6 |
| dust asian | #6 |
| edema severity | #6 |
| strip meniscometry scores | #6 |
| betamethasone oral | #6 |
| agents interferometry | #6 |
| elasticity cutometer | #6 |
| cys ocular | #6 |
| levocabastine effective | #6 |
| tranilast inhibition | #6 |
| signs scored | #6 |
| severe vkc | #6 |
| symptoms vkc | #6 |
| remodeling vkc | #6 |
| inflammatory cell densities | #6 |
| corneal fibroblasts pathogenesis | #6 |
| fva landolt | #6 |
| july correlation | #6 |
| twicedaily instillation | #6 |
| sde ade | #6 |
| sac vkc | #6 |
| 4 9 genes | #6 |
| obstructive mgd patients | #6 |
| severe ocular inflammation | #6 |
| tear meniscus patients | #6 |
| akc refractory | #6 |
| diseases periostin | #6 |
| antiallergic eye | #6 |
| hyperemia swelling | #6 |
| tryptase proliferation | #6 |
| tear eosinophil | #6 |
| chloride eye | #6 |
| conjunctival complications | #7 |
| nonparametric tears | #7 |
| conjunctiva brush | #7 |
| suspension 01 | #7 |
| meniscometry testing | #7 |
| conjunctival inflammatory | #7 |
| pgd2 dependent | #7 |
| injection oedema | #7 |
| neutrophils corneal | #7 |
| 0001 impression | #7 |
| allergic dna | #7 |
| improvements symptom scores | #7 |
| necrotizing anterior | #7 |
| western blotting nfκb | #7 |
| accommodating intraocular lens | #7 |
| surgery cooling | #7 |
| hrtii rcm | #7 |
| sources chemokines | #7 |
| administration fluorescein | #7 |
| conclusion mmc | #7 |
| severe persistent cases | #7 |
| conjunctivitis dry | #7 |
| conjunctivitis risk | #7 |
| vkc gpc | #7 |
| evaluation eyelid | #7 |
| chemotaxis eosinophils | #7 |
| 4 tear | #7 |
| steroidal benzophenones | #7 |
| tear supply | #7 |
| allergic eyelid | #7 |
| development allergic conjunctivitis | #7 |
| eyelid surface | #7 |
| tacrolimus topical steroids | #7 |
| status atopic | #7 |
| pathogenesis subsequent | #7 |
| patients comfort level | #7 |
| mmc observed | #7 |
| examination tear | #7 |
| alpha tears | #7 |
| attendance allergic | #7 |
| ulcer corneal | #7 |
| eczema frequently | #7 |
| tacrolimustreated eyes | #7 |
| hyperemia adverse | #7 |
| increases proliferative | #7 |
| cases preventing | #7 |
| normal blinking | #7 |
| 10 clinical signs | #7 |
| sensitization asian | #7 |
| amniotic membrane patching | #7 |
| conjunctival brush | #7 |
| mucins periodic | #7 |
| eyes ophthalmologists | #7 |
| prostaglandin atopic | #7 |
| crth2 normal | #7 |
| revealed eosinophils | #7 |
| ocular inflammatory disorder | #7 |
| papillae formation | #7 |
| tears th2 | #7 |
| collected brush | #7 |
| age 325 years | #7 |
| corneal lesion | #7 |
| ulcers revealed | #7 |
| cytology differ | #7 |
| incidence meibomian | #7 |
| sensation symptom | #7 |
| tears alpha | #7 |
| mucins tears | #7 |
| pge2 cox2 levels | #7 |
| procedures radioimmunoassay | #7 |
| silicone plugs | #7 |
| superiority placebo | #7 |
| adult blepharitis | #7 |
| concentrations conjunctival | #7 |
| ulceration healthy | #7 |
| tmh measurements | #7 |
| mmc 005 | #7 |
| key prostaglandin | #7 |
| solution bf | #7 |
| rose bengal fluorescein | #7 |
| thought pathogenesis | #7 |
| inhibitor ono2235 | #7 |
| nerves tear | #7 |
| gpc vkc | #7 |
| 006 degree | #8 |
| tnfalpha eosinophils | #8 |
| brush cytology | #8 |
| blink patients | #8 |
| akc subjects | #8 |
| controls seldi | #8 |
| blinking body | #8 |
| itching hyperemia | #8 |
| correlation vital | #8 |
| ccl5 conjunctiva | #8 |
| akc patients controls | #8 |
| conjunctival findings | #8 |
| underwent tear | #8 |
| conjunctival sensation | #8 |
| occlusion lacrimal | #8 |
| graticule scale | #8 |
| transient burning sensation | #8 |
| blinking desiccation | #8 |
| asia cats | #8 |
| il4 enzyme | #8 |
| staining hel | #8 |
| noninfectious corneal | #8 |
| par2 mast cells | #8 |
| oedema scores | #8 |
| trabeculectomy amniotic | #8 |
| pollen odds | #8 |
| diameter acinar | #8 |
| mitomycin post | #8 |
| corneal ulcer | #8 |
| fva measurements | #8 |
| limbalbased conjunctival flap | #8 |
| 4 chemokines | #8 |
| ihc hel | #8 |
| radiation thermography | #8 |
| expressions thought | #8 |
| alterations allergic | #8 |
| corneal scores | #8 |
| patients corneal | #8 |
| surface teros | #8 |
| corneal fibroblasts tnfalpha | #8 |
| fluorescein rose bengal | #8 |
| techniques keratoconjunctivitis | #8 |
| meniscometry tear | #8 |
| ulcers detected | #8 |
| stained hel | #8 |
| sac akc | #8 |
| alterations cornea | #8 |
| definite dry eye | #8 |
| corneal epithelial lesions | #8 |
| pathogenesis test | #8 |
| hoc analysis study | #8 |
| scores teros | #8 |
| teros | #8 |
| betamethasone calcineurin | #8 |
| teros values | #8 |
| flare counts | #8 |
| classified allergic | #8 |
| superficial cells groups | #8 |
| microscopy conjunctival | #8 |
| meniscometry scores | #8 |
| controls brush | #8 |
| conjunctivitis eyes | #8 |
| chemotaxis pgd2 | #8 |
| values slit | #8 |
| infrared radiation thermometry | #8 |
| induced intraocular | #8 |
| rollable intraocular | #8 |
| palpebral bulbar | #8 |
| keratocytes cytokines | #8 |
| stainings schirmer | #8 |
| allergic dibenzazepines | #8 |
| patients vkc | #8 |
| age 170 ± | #8 |
| eye redness | #8 |
| severity corneal | #9 |
| prospective study tacrolimus | #9 |
| sio2 pbs | #9 |
| eye grade | #9 |
| specular microscopic evaluation | #9 |
| ono2235 | #9 |
| patients tacrolimus treatment | #9 |
| shield ulcers | #9 |
| tacrolimus treating | #9 |
| sensitivity conjunctival | #9 |
| sufficient examination | #9 |
| eye normal subjects | #9 |
| differ allergic | #9 |
| conjunctivitis cases | #9 |
| wash solution | #9 |
| symptoms allergic conjunctivitis | #9 |
| blood level tacrolimus | #9 |
| histocytological study | #9 |
| design eyelid | #9 |
| 0001 schirmer | #9 |
| pilocarpine tablets | #9 |
| pretreatment docosahexaenoic | #9 |
| elisa tears | #9 |
| crth2 expression eosinophils | #9 |
| observed obstructive | #9 |
| acid goblet | #9 |
| excision intraoperative | #9 |
| diagnosis conjunctivitis | #9 |
| diseases conjunctivitis | #9 |
| subjective ocular | #9 |
| foreign body sensation | #9 |
| prevalence vkc | #9 |
| concentration tears | #9 |
| untreated asian | #9 |
| hyperemia iop | #9 |
| mmc recurrence | #9 |
| fluorescein rose | #9 |
| cys eye | #9 |
| measurements vital | #9 |
| tear level | #9 |
| tears thermography | #9 |
| prevalence weather | #9 |
| reductase cataract | #9 |
| conjunctival fibroblast | #9 |
| received preserved | #9 |
| pollution conjunctivitis | #9 |
| fatigue dry | #9 |
| stress staining | #9 |
| genes cxc | #9 |
| level pollutants | #9 |
| cobblestone papillae | #9 |
| sensitivity confocal | #9 |
| glaucoma younger age | #9 |
| operatedon eye | #9 |
| superior limbic | #9 |
| injection edema | #9 |
| smart eye | #9 |
| supply superior | #9 |
| vital staining scores | #9 |
| vital stainings | #9 |
| implantation 1cu | #9 |
| clinical ocular findings | #9 |
| cases conjunctivitis | #9 |
| tnfalpha fibroblasts | #9 |
| pathogen allergic | #9 |
| inflammation steroidal | #9 |
| tacrolimus 95 | #9 |
| hel 4 | #9 |
| topical cyclosporine patients | #10 |
| substance tears | #10 |
| shield ulcer | #10 |
| icam1 tnfalpha | #10 |
| meibomian gland obstruction | #10 |
| conjunctivitis atopic | #10 |
| conjunctivitis spring | #10 |
| underwent slit | #10 |
| ophthalmic adolescent | #10 |
| aged conjunctivitis | #10 |
| par2 mast | #10 |
| eye surface | #10 |
| lower tmh | #10 |
| compared eyes | #10 |
| improvement tear | #10 |
| humans conjunctival | #10 |
| measurement strip | #10 |
| crth2 chemotaxis | #10 |
| treatment vkc | #10 |
| chemokines cxc chemokines | #10 |
| diagnosis dry eye | #10 |
| tear cytology | #10 |
| humans mucin | #10 |
| allergic ocular | #10 |
| staining oral | #10 |
| complain | #10 |
| conjunctivitis japan | #10 |
| insufficient local | #10 |
| muc5ac muc16 | #10 |
| evaluation atopic | #10 |
| assessed conjunctival | #10 |
| functions dry | #10 |
| visante optical | #10 |
| resection regrowth | #10 |
| vmr values | #10 |
| status conjunctival | #10 |
| punctal occlusion | #10 |
| muc16 muc5ac | #10 |
| nonallergic conjunctivitis | #10 |
| allergic conjunctivitis spring | #10 |
| proliferation conjunctival | #10 |
| patients ulcers | #10 |
| drugs conjunctival | #10 |
| cytometry il4 | #10 |
| total tear ige | #10 |
| tears 10 | #10 |
| leupeptin benzamidine | #10 |
| sensation ocular | #10 |
| iop hyperemia | #10 |
| eye clinically | #10 |
| bengal stainings | #10 |
| laminin actins | #10 |
| scale tear | #10 |
| levels tears | #10 |
| conjunctival edema | #10 |
| layer alterations | #10 |
| lacrimal puncta | #10 |
| measuring tear | #10 |
| cornea eosinophils | #10 |
| conjunctivitis histamine | #10 |
| central graft | #10 |
| eye infrared | #10 |
| subbasal stromal | #10 |
| produced conjunctival | #10 |
| allergic bronchitis | #10 |
| incubated il4 | #10 |
| staining brush | #10 |
| drop artificial | #11 |
| fibroblasts pathogenesis | #11 |
| genes corneal | #11 |
| levocabastine hydrochloride | #11 |
| cytometry oligonucleotide | #11 |
| 1 month reduction | #11 |
| sensation staining | #11 |
| matched dry | #11 |
| initiation tacrolimus | #11 |
| elasticity treatment | #11 |
| elicited statistically | #11 |
| surgery 13 eyes | #11 |
| prevalence dry eye | #11 |
| landolt visual | #11 |
| patient atopic | #11 |
| purpose metaplasia | #11 |
| test tear | #11 |
| methods conjunctival | #11 |
| amniotic membrane patch | #11 |
| interleukin4 male | #11 |
| higher muc1 | #11 |
| vkc adolescent | #11 |
| smart eye camera | #11 |
| schirmer1 test | #11 |
| coherence dry | #11 |
| anesthesia strabismus | #11 |
| antivcaigg | #11 |
| ophthalmic solution | #11 |
| common conjunctival | #11 |
| palpebral bulbar conjunctiva | #11 |
| hel hne | #11 |
| sensation tear | #11 |
| vkc normal | #11 |
| count conjunctivitis | #11 |
| disease edition | #11 |
| association outpatient | #11 |
| therapy conjunctivitis | #11 |
| vcam1 tnfalpha | #11 |
| vmr fva | #11 |
| tears conjunctival | #11 |
| eosinophils prostaglandin | #11 |
| preserved artificial | #11 |
| weeks papillary | #11 |
| function ocular | #11 |
| diagnosis allergic | #11 |
| keratitis observed | #11 |
| vernal | #11 |
| elisa il4 | #11 |
| vkc | #11 |
| cooling operation | #11 |
| lamp microscope | #11 |
| iop younger | #12 |
| corneal aesthesiometry | #12 |
| density acinar | #12 |
| mgd controls | #12 |
| 1cu iol | #12 |
| lacrimal punctal | #12 |
| radiography tears | #12 |
| fluorescein scores | #12 |
| acids chemokine | #12 |
| fva vmr | #12 |
| mmhg elevation | #12 |
| eye diagnosed | #12 |
| selected severity | #12 |
| fva visual | #12 |
| expression 8 genes | #12 |
| density muc5ac | #12 |
| immunologic rejection | #12 |
| damage height | #12 |
| highspeed highresolution | #12 |
| ccl11 conjunctiva | #12 |
| dermatitis tacrolimus | #12 |
| microscopy efficient | #12 |
| projects tears | #12 |
| extracts pollens | #12 |
| appearance atopic | #12 |
| 001 specimens | #12 |
| 1821 subjects | #12 |
| patients sac | #12 |
| corneal shield | #12 |
| tears conjunctivitis | #12 |
| receptor crth2 | #12 |
| 1cu accommodating | #12 |
| 002 ophthalmic | #12 |
| iop glucocorticoids humans | #12 |
| pemirolast potassium | #12 |
| surface diabetic | #12 |
| conventional slit | #12 |
| controls antibody titers | #12 |
| ulcers squamous | #12 |
| levocabastine patients | #12 |
| findings conjunctival | #12 |
| supratarsal injection | #12 |
| drugs pge2 | #12 |
| keratoplasty glaucoma | #12 |
| biomarker allergic | #12 |
| keratoconjunctivitis patients | #12 |
| leupeptins mast | #12 |
| coated lactoferrin | #12 |
| cornea density | #12 |
| specimens eyes | #12 |
| conjunctival injection | #12 |
| severe binocular | #12 |
| 5ac ophthalmic | #13 |
| treatment allergic conjunctivitis | #13 |
| bengal fluorescein | #13 |
| scraped samples | #13 |
| cell flare | #13 |
| outcomes 01 | #13 |
| ulcers corneal | #13 |
| symptoms conjunctival | #13 |
| conjunctival oedema | #13 |
| coherence viscosupplements | #13 |
| tear functions | #13 |
| upper tarsal | #13 |
| papillary samples | #13 |
| glaucoma younger | #13 |
| months healed | #13 |
| objective signs | #13 |
| compared postsurgical | #13 |
| glaucoma keratoplasty | #13 |
| remodeling relevant | #13 |
| anterior segment photography | #13 |
| called giant | #13 |
| stability vital | #13 |
| dry eye examination | #13 |
| syndrome reactivation | #13 |
| time fluorescein | #13 |
| inflammation tear | #13 |
| corneal complications | #13 |
| interferometry tear | #13 |
| week corneal | #13 |
| conclusions ocular | #13 |
| vmr measurements | #13 |
| specimens levels | #13 |
| fluorometholone fml | #13 |
| epithelial disease | #13 |
| suspensions tacrolimus | #13 |
| thirty eyes | #13 |
| protein conjunctival | #13 |
| japan keratoconjunctivitis | #13 |
| chemokines stimulation | #13 |
| temperature cataract | #13 |
| topical cyclosporine treatment | #13 |
| tear hel | #13 |
| sd105 | #13 |
| schirmers test values | #13 |
| applied operation | #13 |
| aged disposable | #13 |
| improvement vital | #13 |
| keratocytes incubated | #13 |
| blood levels tacrolimus | #13 |
| schirmer1 | #14 |
| clinical corneal | #14 |
| flare count | #14 |
| occlusion dry | #14 |
| blinking patients | #14 |
| factors conjunctivitis | #14 |
| conjunctival allergen challenge | #14 |
| conjunctivitis background | #14 |
| conjunctival muc5ac | #14 |
| eyes 002 | #14 |
| radioimmunoassay tears | #14 |
| bf 01 | #14 |
| epithelial muc5ac | #14 |
| conjunctivitis vernal | #14 |
| secrete mediators | #14 |
| fluorometholone humans | #14 |
| vehicle eye | #14 |
| test rose | #14 |
| fungi adolescent | #14 |
| solutions retrospective | #14 |
| proliferative lesion | #14 |
| conjunctival impression | #14 |
| fibroblast damage | #14 |
| density tear | #14 |
| clinically allergic | #14 |
| higher allergic | #14 |
| visits allergic | #14 |
| cornea endophthalmitis | #14 |
| benzamidines blotting | #14 |
| dry eye controls | #14 |
| mcfg treatment | #14 |
| pilocarpine effective | #14 |
| 14 flare | #14 |
| functions corneal | #14 |
| correlation tear | #15 |
| tranilast anti | #15 |
| firstline drug | #15 |
| olopatadine 01 | #15 |
| superior conjunctiva | #15 |
| mmc female follow | #15 |
| ulcer echinocandins | #15 |
| complications height | #15 |
| giant papillary | #15 |
| bilateral conjunctivitis | #15 |
| rtpcr cytometry | #15 |
| ige ecp | #15 |
| occlusion oct | #15 |
| occlusion rose | #15 |
| complications mmc | #15 |
| examined existence | #15 |
| day bf | #15 |
| effects benzalkonium | #15 |
| surface vital | #15 |
| patients vernal | #15 |
| improvement corneal | #15 |
| eye drop treatment | #15 |
| improvement subjective symptoms | #15 |
| damaged fibroblasts | #15 |
| agents blepharitis | #15 |
| bromobenzenes child | #15 |
| evaluation conjunctival | #15 |
| blepharitis conjunctivitis | #15 |
| receptor pgd2 | #15 |
| basal tear secretion | #15 |
| analysis par2 | #15 |
| ocular surface mucins | #15 |
| corneal recurrence | #15 |
| ocular itching | #15 |
| steroidal cornea | #15 |
| expression realtime pcr | #15 |
| diseases 2020 | #15 |
| tmh values | #15 |
| monitoring tear | #15 |
| cytology brush | #15 |
| mucous discharge | #15 |
| ophthalmology tokyo | #15 |
| ocular acrylic | #15 |
| topical 01 | #15 |
| vkc methods | #15 |
| adherence fibroblasts | #15 |
| investigated corneal | #15 |
| irritation scores | #15 |
| assessment conjunctival | #16 |
| lacrimation | #16 |
| reduction goblet | #16 |
| hours visit | #16 |
| temperature conjunctiva | #16 |
| objective ocular | #16 |
| 2 conjunctival | #16 |
| segment photography | #16 |
| ari administration | #16 |
| measurements tear | #16 |
| odds ratio remission | #16 |
| ige correlation | #16 |
| fungi odds | #16 |
| patients vernal keratoconjunctivitis | #16 |
| total clinical scores | #16 |
| eosinophils receptor | #16 |
| dust allergic | #16 |
| ulcers positive | #16 |
| female goblet | #16 |
| safety 01 | #16 |
| controls papillary | #16 |
| treatment eyelid | #16 |
| alpha ortho | #16 |
| analyzed 005 | #17 |
| muc16 mrna | #17 |
| signs ded | #17 |
| expression eotaxin1 | #17 |
| staining muc1 | #17 |
| 20 normal patients | #17 |
| increased goblet cells | #17 |
| ocular allergic inflammation | #17 |
| betamethasone induced | #17 |
| ceramide gel | #17 |
| drops eyes | #17 |
| warmer treatment | #17 |
| 13 females age | #17 |
| meniscometry | #17 |
| age dry | #17 |
| inflammation blotting | #17 |
| inhibitor ari | #17 |
| fibroblasts damaged | #17 |
| wear soft | #17 |
| sclera trabeculectomy | #17 |
| corneal sensation | #17 |
| conjunctival samples | #17 |
| eyes schirmer | #17 |
| agents cedrus | #17 |
| clearance corneal | #17 |
| strip meniscometry | #17 |
| fibroblasts mcp1 | #17 |
| evaluation inflammatory | #17 |
| initiation objective | #17 |
| dibenzazepines dibenzoxepins | #18 |
| fibroblasts giant | #18 |
| bengal sjogren | #18 |
| differentiation inflammatory cells | #18 |
| induce corneal | #18 |
| concentrations corneal | #18 |
| cytology corneal | #18 |
| technique glaucoma | #18 |
| obstructive dysfunction | #18 |
| inflammation lenses | #18 |
| tear evaporation rate | #18 |
| cd45 inflammatory | #18 |
| cytology decrease | #18 |
| groups spt | #18 |
| male ophthalmic solutions | #18 |
| noncl wearers | #18 |
| tear function | #18 |
| test tears | #18 |
| 30 ige | #18 |
| studies rose | #18 |
| ocular surface status | #18 |
| associations level | #18 |
| ulceration subjects | #18 |
| evaluation tear | #18 |
| complete staining | #18 |
| lower eyes | #18 |
| tnfα inflammatory response | #18 |
| ulcers compared | #18 |
| pollen fungi | #18 |
| higher tears | #18 |
| decrease ocular | #18 |
| conclusion ocular | #18 |
| types dry eye | #18 |
| rantes response | #18 |
| trabeculectomy glaucoma | #18 |
| correlation clinical signs | #18 |
| intraoperative 002 | #18 |
| aged ophthalmic | #19 |
| steroid female | #19 |
| temperature artificial | #19 |
| 3 severe | #19 |
| staining scores | #19 |
| mitomycin ophthalmologic | #19 |
| sma performed | #19 |
| total signs | #19 |
| early efficacy | #19 |
| aged cautery | #19 |
| dha pretreatment | #19 |
| evaluated infrared | #19 |
| operation applied | #19 |
| conjunctivitis topical | #19 |
| 1151 years | #19 |
| seldi analysis | #19 |
| outpatient attendance | #19 |
| sodium 01 | #19 |
| seldi proteinchip | #19 |
| measurements visante | #19 |
| prospective study eyes | #19 |
| ige tear | #19 |
| periostin biomarker | #19 |
| vernal keratoconjunctivitis | #19 |
| inflammatory cells patients | #19 |
| subjects underwent | #19 |
| beta1 il1beta | #19 |
| human conjunctival | #19 |
| effective tacrolimus | #19 |
| eosinophils adhered | #19 |
| microscopy scans | #19 |
| limbal allograft | #19 |
| allergic female humans | #20 |
| echinocandins eye | #20 |
| bilateral agerelated cataract | #20 |
| symptoms allergic | #20 |
| proteins tears | #20 |
| improvements ocular | #20 |
| tears corneal | #20 |
| ulcers cell | #20 |
| summarized based | #20 |
| 022 pg | #20 |
| pollen association | #20 |
| mucin alterations | #20 |
| plaques graded | #20 |
| persistent epithelial defect | #20 |
| patients strip | #20 |
| cytology upper | #20 |
| vernal keratoconjunctivitis vkc | #20 |
| evaluate noninferiority | #20 |
| decreased conjunctival | #20 |
| explain pathogenesis | #20 |
| xerophthalmia adolescent | #20 |
| surface findings | #20 |
| conjunctivitis caused | #20 |
| lower dry | #20 |
| common ocular disorders | #20 |
| treated 01 | #20 |
| conclusion tacrolimus | #20 |
| height tmh | #20 |
| corneal impression | #20 |
| conjunctivitis primary | #20 |
| cultured conjunctiva | #21 |
| eosinophils flow cytometry | #21 |
| radiation thermometer | #21 |
| lipid oxidative | #21 |
| surface mucin | #21 |
| induced topical | #21 |
| patients cedar | #21 |
| acuity assessment | #21 |
| patients concomitant treatment | #21 |
| tears blood | #21 |
| levels hel | #21 |
| conclusions topical | #21 |
| preventing corneal | #21 |
| methane nonmethane hydrocarbons | #21 |
| symptoms include | #21 |
| eye control | #21 |
| reaction tears | #21 |
| microscopy patients | #21 |
| fluorescence postoperative | #21 |
| film lipid | #21 |
| ocular symptoms signs | #21 |
| peripheral blood eosinophils | #21 |
| adhesion fibroblast | #21 |
| cornea clinical | #21 |
| eye smaller | #21 |
| reduction topical | #21 |
| conjunctiva role | #21 |
| crth2 expressed | #21 |
| keratoconjunctivitis atopic | #21 |
| ige groups | #21 |
| negative lower | #22 |
| fibroblasts anti | #22 |
| haze photorefractive | #22 |
| accommodation amplitude | #22 |
| 005 topical | #22 |
| types ocular | #22 |
| correlation humidity | #22 |
| muc5ac patients | #22 |
| serum periostin patients | #22 |
| eyes nerve | #22 |
| therapies allergic | #22 |
| fluorescein staining | #22 |
| mgd adult | #22 |
| 01 tacrolimus | #22 |
| flare anterior | #22 |
| epithelial lipid | #22 |
| subjects squamous | #23 |
| labeling tears | #23 |
| score deqs | #23 |
| pge2 supernatants | #23 |
| tear dynamics | #23 |
| preschool conjunctivitis | #23 |
| 215 ± | #23 |
| solution compared | #23 |
| diseases diclofenac | #23 |
| cooling applied | #23 |
| solution corneal | #23 |
| il4 tnf | #23 |
| corneal fluorescein | #23 |
| layer interferometry | #23 |
| patients topical steroids | #23 |
| hrt confocal | #23 |
| tests adenovirus | #23 |
| function mucin | #23 |
| prospectively surgery | #23 |
| lamp examinations | #23 |
| palpebral conjunctiva | #23 |
| 5 females | #23 |
| 01 severe | #23 |
| blood concentration tacrolimus | #23 |
| disease atopic | #23 |
| histamine development | #24 |
| tarsal conjunctiva | #24 |
| tokyo dental | #24 |
| layer tear | #24 |
| interleukin4 oligonucleotide | #24 |
| vkc patients | #24 |
| vital staining | #24 |
| surface tear | #24 |
| 27yearold male patient | #24 |
| local allergic reaction | #24 |
| signs serum | #24 |
| control tear | #24 |
| conjunctiva diabetes | #24 |
| dermatitis improved | #24 |
| formation allergic | #24 |
| diseases web | #24 |
| fungal corneal | #24 |
| patients tacrolimus ointment | #24 |
| warming device | #24 |
| cell meter | #24 |
| edema drug | #24 |
| samples conjunctival | #24 |
| bengal tears | #24 |
| ocular allergies | #24 |
| atopic eosinophils humans | #25 |
| superficial cells | #25 |
| rtpcr rsv | #25 |
| confocal prospective | #25 |
| dynamics tear | #25 |
| antigen conjunctiva | #25 |
| level tears | #25 |
| staining goblet | #25 |
| schedule eosinophil | #25 |
| eyes epithelial | #25 |
| corneal plaques | #25 |
| steroid eye | #25 |
| vcam1 activated | #25 |
| patients atopic diseases | #25 |
| density squamous | #25 |
| protein rtpcr | #25 |
| bengal scores | #25 |
| slitlamp examinations | #25 |
| 0001 dry | #25 |
| vkc compared | #25 |
| rsv rtpcr | #25 |
| wheal diameter | #26 |
| 100 nylon | #26 |
| lnfs | #26 |
| postkeratoplasty glaucoma | #26 |
| smallincision cataract surgery | #26 |
| eyes topical | #26 |
| diseases ambient | #26 |
| dmem f12 medium | #26 |
| keratoconjunctivitis caused | #26 |
| level il4 | #26 |
| actins collagen | #26 |
| 01 topical | #26 |
| statistical decrease | #26 |
| corneal ulcers | #26 |
| specific ige positivity | #26 |
| rapid epithelialization | #26 |
| human α defensin | #26 |
| subjects measuring | #26 |
| correlated corneal | #26 |
| symptoms itching | #26 |
| conclusions improvement | #26 |
| treatment meibomian | #26 |
| damage adhesion | #26 |
| singletreatment groups | #26 |
| conjunctival inflammation | #26 |
| acinar unit | #26 |
| conjunctivitis | #26 |
| tbut tear | #26 |
| adhered fibroblasts | #26 |
| solutions corneal | #26 |
| 005 immunoreactive | #26 |
| slit lamp examinations | #26 |
| aureus detected | #26 |
| factor exacerbation | #27 |
| lymphocytes specimens | #27 |
| therapy conjunctiva | #27 |
| reaction sensation | #27 |
| cytometry chemotaxis | #27 |
| oct prospective | #27 |
| antibodies brush | #27 |
| child cytological | #27 |
| tear ocular | #27 |
| associations prevalence | #27 |
| epinastine | #27 |
| eosinophils fibroblasts | #27 |
| 01 cyclosporine | #27 |
| density subbasal | #27 |
| alpha eosinophils | #27 |
| prescribed topical | #27 |
| interleukin4 polymerase | #27 |
| 005 symptoms | #27 |
| conjunctival epithelial | #27 |
| objective scores | #28 |
| conjunctiva dexamethasone | #28 |
| chemotactic activity eosinophils | #28 |
| prevalence allergic diseases | #28 |
| giant papillae | #28 |
| papillae patients | #28 |
| stress atopic | #28 |
| provide relief | #28 |
| assay eosinophils | #28 |
| eosinophil adherence | #28 |
| il13 il1beta | #28 |
| diseases proliferative | #28 |
| conjunctival epithelial cells | #28 |
| underwent immunohistochemical | #28 |
| assessment tear | #28 |
| corneal ulceration | #28 |
| severe ocular | #28 |
| corneal vivo | #28 |
| 2 iol | #28 |
| 4 5ac | #28 |
| solutions ophthalmologic | #28 |
| ophthalmic | #28 |
| ketotifen fumarate | #29 |
| numbers inflammatory | #29 |
| aged thermography | #29 |
| allergic regulation | #29 |
| studies conjunctivitis | #29 |
| corneal conjunctival | #29 |
| performed morphometric | #29 |
| disease periostin | #29 |
| scores schirmer | #29 |
| rosebengal | #29 |
| sac compared | #29 |
| inhibited tranilast | #29 |
| cys treatment | #29 |
| conjunctiva dose | #29 |
| eye mask | #29 |
| thermography adolescent | #29 |
| 5ac mucins | #29 |
| flare cell | #29 |
| inhibitors pollen | #30 |
| dermatitis efficacy | #30 |
| minutes visit | #30 |
| tear ige | #30 |
| fibroblasts protease | #30 |
| tear serum | #30 |
| conjunctivitis humans | #30 |
| regrowth observed | #30 |
| conjunctivitis patients | #30 |
| ocular surface alterations | #30 |
| common adverse reaction | #30 |
| palpebral | #30 |
| atopic diagnostic | #30 |
| syndromes equipment | #30 |
| redness eye | #30 |
| expressed crth2 | #30 |
| infection conjunctival | #30 |
| specificity tears | #30 |
| effective artificial | #30 |
| conjunctiva cells | #30 |
| mucins ophthalmic | #30 |
| eye common | #30 |
| recruitment day | #30 |
| il2r serum | #30 |
| symptoms accompanying | #30 |
| inflammation atopic | #31 |
| acuity fva | #31 |
| fibroblasts pcr | #31 |
| ige negative | #31 |
| properties tears | #31 |
| epithelial mucins | #31 |
| scores corneal | #31 |
| levels july | #31 |
| expressed eosinophils | #31 |
| pathogenesis corneal | #31 |
| combinations eosinophils | #31 |
| neutrophils severity | #31 |
| atopic 10 | #31 |
| vegf cultured | #31 |
| disease summarized | #31 |
| hel levels | #31 |
| schirmer scores | #31 |
| dermatitis purpose | #31 |
| worse observed | #31 |
| meibomian gland secretion | #31 |
| substantial interrater agreement | #32 |
| diagnosed dry | #32 |
| tgfbeta1 il1beta | #32 |
| reduced steroid | #32 |
| signs improved | #32 |
| tear meniscus height | #32 |
| prostaglandin cell | #32 |
| limbus cornea | #32 |
| deqs | #32 |
| analysis tears | #32 |
| keratoconjunctivitis | #32 |
| conjunctival cells | #32 |
| sign scores | #32 |
| schirmer test values | #32 |
| expressibility | #32 |
| eye sjögren | #32 |
| western blotting effects | #32 |
| numbers quantitative | #33 |
| allergic double | #33 |
| seasonal young | #33 |
| 4 grades | #33 |
| muc 1 | #33 |
| count prostaglandin | #33 |
| film break | #33 |
| atopic skin disease | #33 |
| signs evaluated | #33 |
| iop induced | #33 |
| haze score | #33 |
| conclusions confocal | #33 |
| visante | #33 |
| edema correlated | #33 |
| immunoglobulin interferometry | #33 |
| levocabastine | #33 |
| ige histamine | #33 |
| eyes corneal | #34 |
| intraocular pressure surgery | #34 |
| fluorometholone glucocorticoids | #34 |
| alpha fibroblasts | #34 |
| clinical signs patients | #34 |
| treatment mgd | #34 |
| conjunctiva cytokines | #34 |
| fibroblasts purpose | #34 |
| bengal staining | #34 |
| 01 effective | #34 |
| proteinchip array | #34 |
| 10 objective | #34 |
| eye 10 | #34 |
| il1beta tgfbeta1 | #34 |
| therapy histamine | #34 |
| interrater reproducibility | #35 |
| cyclosporine cys | #35 |
| objective symptoms | #35 |
| hypertension tacrolimus | #35 |
| virus capsid antigen | #35 |
| tear stability | #35 |
| eye 20 | #35 |
| mucins prospective | #35 |
| 6 months conclusion | #35 |
| adult asthenopia | #35 |
| eyes acrysof | #36 |
| diseases eosinophil | #36 |
| differential dry | #36 |
| severe allergic | #36 |
| tear samples | #36 |
| humans keratoconjunctivitis | #36 |
| resection 005 | #36 |
| functional visual acuity | #36 |
| efficacy groups | #36 |
| ocular surface inflammation | #36 |
| tear clearance | #36 |
| schirmer 1 | #36 |
| anterior scleritis | #36 |
| vdt users | #36 |
| measured tear | #36 |
| laser flarecell meter | #37 |
| scleritis episcleritis | #37 |
| conducted compliance | #37 |
| delefilcon | #37 |
| wellrecognized risk | #37 |
| eyelid skin | #37 |
| tacrolimus 12 | #37 |
| oct effective | #37 |
| tenon anesthesia | #37 |
| contact lens surface | #37 |
| induced iop | #37 |
| 002 mmc | #37 |
| tears tumor | #37 |
| schirmer 1 test | #37 |
| recurrence corneal | #37 |
| cac japanese | #38 |
| pemirolast | #38 |
| gland lipid | #38 |
| allergic cromolyn | #38 |
| device eye | #38 |
| aged olopatadine | #38 |
| 002 mitomycin | #38 |
| post cataract | #38 |
| exhibited correlation | #38 |
| phacoemulsification implantation | #38 |
| atopic dry | #39 |
| degree 20 | #39 |
| response pretreatment | #39 |
| tests diagnostic accuracy | #39 |
| infiltration corneal | #39 |
| solutions patient | #39 |
| 005 oct | #39 |
| patients dry eye | #39 |
| 0001 specimens | #39 |
| cells conjunctiva | #39 |
| accommodating intraocular | #39 |
| tears eye | #39 |
| cyclosporine dry | #39 |
| conjunctiva limbus | #39 |
| endothelial rejection | #40 |
| pharmacology clinical efficacy | #40 |
| samples eyes | #40 |
| drops corneal | #40 |
| subjects specimens | #40 |
| tmh | #40 |
| decreased inflammation | #40 |
| biomarkers conjunctiva | #40 |
| ulcers control | #40 |
| acid chemokine | #40 |
| eye patients | #40 |
| vegf il1beta | #41 |
| stimulate vascular | #41 |
| eyes superior | #41 |
| treatment dry | #41 |
| treated topical | #41 |
| il1beta vegf | #41 |
| ecp concentrations | #41 |
| conjunctivitis gpc | #41 |
| pollution severe | #41 |
| α pge2 | #41 |
| homologous visual | #41 |
| epitheliopathy | #41 |
| allergens conjunctivitis | #42 |
| efficient noninvasive | #42 |
| break time | #42 |
| corneal epithelia | #42 |
| scans underwent | #42 |
| october july | #42 |
| day eye | #42 |
| microscopy central | #43 |
| meniscus treatment | #43 |
| eyelid edema | #43 |
| revised 2010 | #43 |
| keratolimbal | #43 |
| surface years | #43 |
| cytology revealed | #43 |
| conjunctival hyperemia | #43 |
| instability decreased | #43 |
| limbus corneal | #43 |
| diseases 2017 | #43 |
| hydrocarbons data | #43 |
| rollable | #43 |
| activated il4 | #44 |
| cautery female | #44 |
| elasticity patients | #44 |
| tear meniscus | #44 |
| agents keratoconjunctivitis | #44 |
| il1beta il4 | #44 |
| tryptase par2 | #44 |
| oct assessment | #44 |
| subjective symptom | #44 |
| abovementioned drugs | #44 |
| tacrolimus treatment | #44 |
| eye 0001 | #44 |
| epithelial defect | #44 |
| patients rhinoconjunctivitis | #44 |
| collagens fibronectin | #44 |
| formation corneal | #45 |
| surface inflammation | #45 |
| japan particulate | #45 |
| correlation inflammation | #45 |
| metaplasia mucin | #45 |
| adult chemotaxis | #45 |
| fourgrade scale | #45 |
| rose bengal staining | #45 |
| metaplasia grade | #45 |
| topical tacrolimus treatment | #45 |
| users contact | #45 |
| body sensation | #45 |
| fibroblasts expression | #45 |
| graded 3 | #45 |
| fibroblasts eosinophils | #45 |
| recruiting chemokines | #45 |
| laser microscopy | #45 |
| understanding ocular | #45 |
| signs score | #45 |
| bovine enteric | #45 |
| 24 seconds | #45 |
| micafungin mcfg | #45 |
| elevation iop | #45 |
| surgery uncorrected | #45 |
| case corneal | #45 |
| inflammation ocular surface | #45 |
| superficial punctate keratitis | #45 |
| posttreatment findings | #46 |
| 17 japanese patients | #46 |
| il13 serum | #46 |
| graticule | #46 |
| tryptases regulation | #46 |
| staining conjunctival | #46 |
| fluorometholone | #46 |
| efficacy combined therapy | #46 |
| efficacy 01 | #46 |
| suspension effective | #46 |
| seconds controls | #46 |
| staining inflammatory | #46 |
| status ocular | #46 |
| conjunctival | #46 |
| surface disease | #46 |
| corneal cells | #46 |
| purpose efficacy | #47 |
| rate ocular | #47 |
| visante oct | #47 |
| ulcer score | #47 |
| blood level | #47 |
| diameter plant | #47 |
| patients 01 | #47 |
| allergic female histamine | #47 |
| suspension 4 | #47 |
| positive muc5ac | #47 |
| stromal nerve | #48 |
| eyes month | #48 |
| eyelid warming | #48 |
| muc5ac mrna | #48 |
| implantation acrysof | #48 |
| cyclosporine ophthalmic | #48 |
| sac patients | #48 |
| dexamethasone anti | #48 |
| complications corneal | #48 |
| stimulation chemokine | #48 |
| brush cytology specimens | #48 |
| enhanced benefits | #48 |
| fibroblasts incubated | #49 |
| visits air | #49 |
| eosinophils epithelium | #49 |
| concentrations tears | #49 |
| ocular signs | #49 |
| objective findings | #49 |
| keratocytes fibroblasts | #49 |
| cxc chemokine genes | #49 |
| male tears | #49 |
| adult ca125 | #49 |
| tacrolimus female | #49 |
| 1cu | #49 |
| trabeculectomy eyes | #49 |
| expression crth2 | #49 |
| trabeculectomy mitomycin | #50 |
| patient eyes | #50 |
| disposable soft | #50 |
| decreased tear | #50 |
| schirmers test | #50 |
| ulcers purpose | #50 |
| total severity score | #50 |
| inflammation conjunctiva | #50 |
| test ocular | #50 |
| aged blinking | #50 |
| measuring corneal | #50 |
| dyes fluorophotometry | #50 |
| meniscus height | #50 |
| 4 normal controls | #50 |
| ocular surface cells | #51 |
| effects docosahexaenoic acid | #51 |
| members japan | #51 |
| scls | #51 |
| lenses scls | #51 |
| crth2 expression | #51 |
| markers atopic | #51 |
| reduction score | #51 |
| diagnosis dry | #51 |
| inflammation cataract | #51 |
| cells brush | #51 |
| periostin patients | #51 |
| biomarker diseases | #52 |
| month initiation | #52 |
| stability corneal | #52 |
| inflammation decline | #52 |
| examination parameters | #52 |
| eyelid margins | #52 |
| reaction vehicle | #52 |
| atopic groups | #52 |
| pcr tgf | #52 |
| tears tomography | #52 |
| severity objective | #52 |
| eye normal | #52 |
| acuity values | #53 |
| bromfenac | #53 |
| stromal nerves | #53 |
| differential eosinophil | #53 |
| suspension treatment | #54 |
| chloride bak | #54 |
| 005 month | #54 |
| presence rsv | #54 |
| vegf protein secretion | #54 |
| scores tear | #54 |
| oxidation adolescent | #54 |
| obstructive mgd | #54 |
| limbic keratoconjunctivitis | #54 |
| lacrimal glands | #54 |
| adult conjunctivitis | #55 |
| conjunctiva drug | #55 |
| antagonists allergic | #55 |
| ocular signs symptoms | #55 |
| aged pollen | #55 |
| combinedtreatment | #55 |
| surface clinical | #55 |
| local cytokine production | #55 |
| atopic enterotoxins | #55 |
| epithelial cells expression | #55 |
| plant pollens | #56 |
| topical adolescent | #56 |
| mechanism giant | #56 |
| ded adult | #56 |
| 3 dry | #56 |
| specular microscopic | #56 |
| solution placebo | #56 |
| atopic patients | #56 |
| mucin layer | #56 |
| mucin2 mucin4 | #56 |
| film ocular | #56 |
| eosinophil cationic | #56 |
| allergies adolescent | #56 |
| dysfunction atopic | #56 |
| cornea cyclooxygenase | #56 |
| pain photophobia | #56 |
| chemotactic responses | #57 |
| penetrating limbus | #57 |
| accommodating iol | #57 |
| insensible administration | #57 |
| humans interleukin4 | #57 |
| giant papillary conjunctivitis | #57 |
| inflammation pge2 | #57 |
| staining tear | #58 |
| schiff staining | #58 |
| alpha defensins | #58 |
| seventyeight eyes | #58 |
| papilla formation | #58 |
| objective sign | #58 |
| maximum blood concentration | #58 |
| drop treatment | #58 |
| pm25 prevalence | #59 |
| intraoperative mitomycin | #59 |
| disease eyes | #59 |
| type allergic | #59 |
| findings criteria | #59 |
| tear instability | #59 |
| signs severe | #60 |
| evaluation items | #60 |
| compared 0001 | #60 |
| pcr severe | #60 |
| mmc 2 | #60 |
| syndromes female | #60 |
| tacrolimus ointment treatment | #60 |
| diabetic corneal | #60 |
| release inhibitor | #60 |
| daily disposable | #60 |
| nonsteroidal blotting | #61 |
| thermography adult | #61 |
| correlation patients | #61 |
| punctal | #61 |
| values tended | #62 |
| eyes 16 | #62 |
| specimens histopathologic | #62 |
| eotaxin1 expression | #62 |
| prostaglandin patients | #62 |
| expression eyes | #62 |
| amplitude accommodation | #62 |
| allergen mediated | #62 |
| combination epithelium | #62 |
| total clinical | #62 |
| hypersensitivity japan | #63 |
| oral pilocarpine | #63 |
| ulcer endophthalmitis | #63 |
| chamber body | #63 |
| micafungin treatment | #63 |
| sac age | #63 |
| il4 role | #63 |
| corneal stem | #63 |
| corneal erosion | #63 |
| patient corneal | #63 |
| conjunctiva patients | #63 |
| radioimmunoassay respiratory | #64 |
| density inflammatory | #64 |
| factor allergic | #64 |
| evaluation corneal | #64 |
| dexamethasone production | #64 |
| cornea dry | #64 |
| eye adolescent | #64 |
| il4 culture | #64 |
| positive mucin | #64 |
| live rsv | #65 |
| viral radioimmunoassay | #65 |
| microscope methods | #65 |
| conclusions corneal | #65 |
| mucins rna | #65 |
| tears biomarkers | #65 |
| dust house | #65 |
| layer speed | #66 |
| cases atopic | #66 |
| diagnosis therapies | #66 |
| treatment immunosuppressive agents | #66 |
| surface epithelial | #66 |
| persistent epithelial | #67 |
| effects 01 | #67 |
| period oral | #67 |
| agents keratoplasty | #67 |
| cyclosporine eye | #67 |
| 003 treatment | #67 |
| female fluorophotometry | #67 |
| eye dry | #68 |
| ointment treatment | #68 |
| housedust | #68 |
| time vital | #68 |
| counter drugs | #69 |
| patients eosinophils | #69 |
| occlusion 005 | #69 |
| glaucoma graft | #69 |
| fibroblasts corneal | #69 |
| ophthalmic solutions | #69 |
| aged tears | #69 |
| fibroblasts examined | #69 |
| schirmer test | #70 |
| 1436 patients | #70 |
| visit 4 | #70 |
| values rose | #70 |
| 22 eyes | #70 |
| crth2 pgd2 | #70 |
| rhinoconjunctivitis allergic | #70 |
| crth2 receptor | #70 |
| dust 20 | #71 |
| drops treatment | #71 |
| factors tears | #71 |
| allergic dermatitis | #71 |
| lenses dry | #71 |
| tear production | #72 |
| bulbar conjunctiva | #72 |
| glaucoma trabeculectomy | #72 |
| 16 eyes | #72 |
| ige eosinophil | #72 |
| liquid conjunctiva | #73 |
| fml | #73 |
| extraction conjunctiva | #73 |
| antiallergic agent | #73 |
| punctate keratopathy | #73 |
| fluorophotometry humans | #73 |
| pollution prevalence | #73 |
| epithelial structure | #73 |
| pyridines pyrimidinones | #73 |
| surface mucins | #73 |
| immunosuppressive treatment patients | #73 |
| agents intraocular | #74 |
| eosinophils expressed | #74 |
| inflammatory cell numbers | #74 |
| mcfg | #74 |
| tacrolimus patients | #74 |
| iol acrysof | #74 |
| evaluation dry | #74 |
| improved infrared | #75 |
| dust epidemiologic | #75 |
| completely controlled | #75 |
| 1 month baseline | #75 |
| pilocarpine prospective | #75 |
| cedar pollen | #75 |
| healthy individuals patients | #75 |
| laser flare | #75 |
| ccchemokine | #76 |
| agents interleukin4 | #76 |
| guidelines allergic | #76 |
| interleukin4 rna | #76 |
| lower tear | #77 |
| signs treatment | #77 |
| cytology samples | #77 |
| chemical mediator | #77 |
| surgery technique | #77 |
| excision recurrence | #77 |
| capilia | #77 |
| studies suspensions | #77 |
| slight elongation | #77 |
| cornea module | #77 |
| ophthalmological elasticity | #77 |
| vegf tgfbeta1 | #77 |
| cytokines stimulate | #77 |
| concentration il2 | #78 |
| japanese guideline | #78 |
| signs observed | #78 |
| concomitant tacrolimus | #78 |
| pollen compared | #78 |
| drops 1 | #78 |
| severity ocular | #78 |
| type allergy | #79 |
| injection reduction | #79 |
| extended wear | #79 |
| inhibitors leupeptin | #79 |
| dry eye | #79 |
| glaucoma penetrating | #79 |
| allergic environmental | #79 |
| effects corneal | #79 |
| il4 ige | #79 |
| permeability cornea | #79 |
| ocular pain | #79 |
| medications required | #80 |
| questionnaires tears | #80 |
| mediated par2 | #80 |
| mgd patients | #80 |
| assay epithelial | #80 |
| decreased dry | #81 |
| vegf concentration | #81 |
| antigens histamine | #81 |
| patients conjunctivitis | #82 |
| acrysof iol | #82 |
| atopic dermatitis study | #82 |
| caused insufficient | #82 |
| cytology performed | #82 |
| prostaglandin reverse | #82 |
| data tacrolimus | #83 |
| expression corneal | #83 |
| dental college | #83 |
| tear lipid | #83 |
| patients staphylococcus aureus | #83 |
| complications lenses | #83 |
| papillae | #84 |
| schirmer | #84 |
| earlier published data | #84 |
| correlation corneal | #84 |
| cytokines vegf | #84 |
| epithelium ocular | #84 |
| temperature patients | #85 |
| alterations basal | #85 |
| combined penetrating | #85 |
| 18 pg | #85 |
| inhibitors tryptases | #85 |
| 5 grades | #85 |
| hyperemia induced | #85 |
| patients dry | #85 |
| human reverse | #85 |
| scleritis patients | #85 |
| treatment odds ratio | #85 |
| discharge evaluated | #86 |
| acuity accommodation | #86 |
| sligkv | #86 |
| daily outpatient | #86 |
| 284 years | #86 |
| edema scores | #86 |
| inflammation eye | #86 |
| pharmacologic intervention | #86 |
| patients eyelid | #86 |
| confocal ophthalmic | #87 |
| detection limit assay | #87 |
| tacrolimus young | #87 |
| tacrolimus reduced | #87 |
| post keratoplasty | #88 |
| disease conjunctiva | #88 |
| cells keratocytes | #88 |
| tears | #88 |
| daily weather conditions | #88 |
| regulation muc5ac | #88 |
| sclera surgical | #88 |
| eyes 30 | #89 |
| tears visual | #89 |
| tryptase inhibitors | #89 |
| assessment dry | #89 |
| findings severe | #89 |
| seasonal perennial | #89 |
| lower corneal | #90 |
| early ocular | #90 |
| months signs | #90 |
| temperature cornea | #90 |
| dressings chronic | #90 |
| cytocentrifuge preparations | #90 |
| tears adult | #90 |
| decrease corneal | #90 |
| glands microscopy | #90 |
| lenses extended | #91 |
| film breakup | #91 |
| exposure japan | #92 |
| laser cell | #92 |
| procedures phacoemulsification | #92 |
| techniques trabeculectomy | #92 |
| eye corneal | #92 |
| patients correlation | #93 |
| stromal corneal | #93 |
| solutions tears | #93 |
| regulation muc1 | #93 |
| treatment noninfectious | #93 |
| eye cataract surgery | #93 |
| 005 complications | #93 |
| tears administration | #93 |
| conjunctival specimens | #93 |
| 7 visit | #93 |
| preschool conjunctiva | #93 |
| drug fibroblasts | #93 |
| reaction physical | #94 |
| exposure exhaust | #94 |
| case allergic | #94 |
| pollution weather | #94 |
| classification pathogenesis | #94 |
| pgd2 crth2 | #94 |
| eye higher | #95 |
| induced pgd2 | #95 |
| twentyeight eyes | #95 |
| studies tears | #95 |
| relevant factor | #95 |
| eosinophils patients | #95 |
| study cyclosporine | #96 |
| staining fluorescein | #96 |
| 128 eyes | #96 |
| protein eosinophilia | #96 |
| higher eyes | #96 |
| score objective | #96 |
| treatment ecp | #97 |
| 1month treatment | #97 |
| 4 alterations | #97 |
| cells hel | #97 |
| production pge2 | #97 |
| meniscus patients | #98 |
| eyes study | #98 |
| eyes positive | #98 |
| eye tear | #98 |
| staining schirmer | #98 |
| vdts | #98 |
| 005 recurrence | #99 |
| solution improved | #99 |
| pseudophakic patients | #99 |
| equivalent 4 | #99 |
| japan post | #99 |
| management ocular | #99 |
| surgery 6 months | #99 |
| cytology evaluation | #99 |
| terminals contact | #100 |
| ulcer patient | #100 |
| postoperatively statistically | #100 |
| conjunctiva corneal | #100 |
| cells severity | #100 |
| allergic atopic | #100 |
| confocal scanning | #100 |
| ointments tacrolimus | #100 |
| local pattern | #100 |
| corneal abnormalities | #100 |
| fibroblasts 2 | #101 |
| eyes 10 | #101 |
| pathogenesis atopic | #101 |
| keratolimbal allograft | #102 |
| agents conjunctivitis | #102 |
| therapy conjunctival | #102 |
| effects tranilast | #102 |
| disease classified | #102 |
| pathogenesis allergic | #102 |
| severe atopic | #102 |
| washing solution | #103 |
| subjective comfort | #103 |
| prevalence dry | #103 |
| mediated protease | #103 |
| chemotaxis experiments | #103 |
| topical cyclosporine | #104 |
| values vital | #104 |
| syndrome epstein | #104 |
| topic premedication | #104 |
| groups dry | #104 |
| patients bf | #104 |
| allergic cytokines | #104 |
| events scores | #104 |
| differences ocular | #104 |
| tears young | #104 |
| conjunctival impression cytology | #105 |
| wearing contact | #105 |
| baseline initiation | #105 |
| role staphylococcal | #105 |
| child conjunctival | #105 |
| inflammation diagnosis | #105 |
| aged amnion | #105 |
| parameters ocular | #106 |
| adhesion fibroblasts | #106 |
| 14 eyes | #106 |
| pressure keratoplasty | #106 |
| microscopy evaluation | #106 |
| conjunctiva cornea | #106 |
| superficial punctate | #107 |
| corneal keratocytes | #107 |
| patients ded | #107 |
| eotaxin1 | #107 |
| levels radioimmunoassay | #108 |
| resins aged | #108 |
| film instability | #108 |
| conjunctiva | #108 |
| acuity acrylic | #108 |
| lipid layer | #108 |
| topical tacrolimus | #108 |
| dry mouth symptoms | #108 |
| scores symptoms | #108 |
| induces chemotaxis | #108 |
| 4 dry | #109 |
| tear evaporation | #109 |
| asian dust | #109 |
| level tacrolimus | #109 |
| effects dha | #109 |
| corneal inflammatory | #109 |
| il4 human | #109 |
| controls inflammatory | #110 |
| lacrimal salivary | #110 |
| eyes 9 | #110 |
| dysfunction mgd | #110 |
| increased evaporation | #110 |
| japanese guidelines | #110 |
| conjunctival epithelium | #110 |
| steroids administration | #110 |
| topical instillation | #111 |
| severity markers | #111 |
| eye camera | #112 |
| vcam1 antibody | #112 |
| papillary conjunctivitis | #113 |
| solutions platelet | #113 |
| anterior segment inflammation | #113 |
| pcr rsv | #113 |
| dibenzoxepins | #113 |
| strabismus surgery | #113 |
| lesions atopic | #114 |
| eye irritation | #114 |
| diagnosed allergic | #114 |
| layer patients | #114 |
| grading scores | #114 |
| incision cataract | #114 |
| sjögrens syndrome patients | #115 |
| male mucin | #115 |
| conjunctival cell | #115 |
| 13 eyes | #115 |
| allergic eye | #115 |
| cholinergic treatment | #115 |
| goblet cell density | #115 |
| findings severity | #115 |
| seconds 0001 | #115 |
| selective histamine | #116 |
| edition revised | #116 |
| ophthalmology prevalence | #117 |
| viscosupplements aged | #117 |
| samples stained | #117 |
| patients seasonal | #117 |
| cooling increased | #117 |
| metaplasia mucins | #117 |
| asia dust | #117 |
| effects docosahexaenoic | #118 |
| generation pge2 | #118 |
| sag genes | #118 |
| molecule1 interleukin4 | #118 |
| immunologic receptors prostaglandin | #118 |
| revealed higher | #119 |
| topical steroids | #119 |
| chemotaxis induced | #119 |
| 39 mmhg | #119 |
| skin elasticity | #119 |
| acuity distance | #119 |
| week 005 | #119 |
| iop observed | #119 |
| matter prevalence | #120 |
| syndromes epithelium | #120 |
| mitomycin ophthalmic | #121 |
| mitomycinc mmc | #121 |
| levels histamine | #121 |
| distance corrected | #121 |
| soft lenses | #121 |
| chronic allergic | #122 |
| male ointments | #123 |
| adult conjunctiva | #123 |
| titers ebv | #123 |
| collagen conjunctiva | #123 |
| artificial tear | #123 |
| area corneal | #124 |
| eosinophils cell | #124 |
| activity corneal | #125 |
| conjunctival tissues | #125 |
| proteaseactivated receptor2 | #126 |
| damage severe | #126 |
| month reduced | #126 |
| 05ng | #127 |
| subjects vivo | #127 |
| patients atopic | #127 |
| nerves studied | #127 |
| soft contact lenses | #128 |
| gamma increase | #128 |
| 9 genes | #128 |
| elisa levels | #129 |
| combination steroids | #129 |
| 361 ± | #129 |
| acds | #129 |
| fibroblast viability | #129 |
| patients insignificant | #130 |
| fva | #130 |
| functional visual | #130 |
| disease cornea | #131 |
| antigen hladr | #131 |
| 5ac | #132 |
| resection severe | #132 |
| cataract phacoemulsification | #132 |
| eye drop | #132 |
| management allergic | #132 |
| eyes fluorescein | #132 |
| treated tacrolimus | #133 |
| keratoplasty adult | #133 |
| proteins mucin | #133 |
| 19 normal subjects | #133 |
| skin water | #133 |
| gene transcription levels | #133 |
| acrylic iol | #134 |
| pcr hla | #134 |
| density negative | #134 |
| normal conjunctival | #134 |
| surface examination | #134 |
| specimens vivo | #135 |
| solutions phacoemulsification | #135 |
| iop treatment | #136 |
| stress status | #136 |
| ophthalmological dry | #137 |
| dry eye patients | #137 |
| severity 10 | #137 |
| antiallergic properties | #137 |
| ocular surface | #137 |
| eosinophil adhesion | #137 |
| asian dust storms | #138 |
| eosinophil cationic protein | #138 |
| iol groups | #138 |
| protein ecp | #139 |
| authors technique | #139 |
| allergic dogs | #139 |
| ratio remission | #139 |
| suppressed pretreatment | #140 |
| allergic patients | #141 |
| aminobenzoates anti | #141 |
| inflammation prostaglandin | #141 |
| interleukin1 interleukin13 | #142 |
| findings upper | #142 |
| improvements symptom | #142 |
| olopatadine hydrochloride | #143 |
| combination rapid | #143 |
| 52 mmhg | #144 |
| cornea cyclosporine | #144 |
| determine central | #144 |
| studies scleritis | #144 |
| symptoms ocular | #145 |
| specimens patient | #145 |
| recordable | #145 |
| eye syndromes | #145 |
| reticular basement membrane | #146 |
| findings adolescent | #146 |
| virus pathogen | #146 |
| eye clinical | #146 |
| underwent evaluation | #146 |
| human conjunctiva | #146 |
| schiff reaction | #146 |
| fibroblasts alpha | #146 |
| impression cytology | #147 |
| 263 years | #147 |
| diagnosis atopic | #147 |
| dscg | #147 |
| required type | #147 |
| hne 4 | #147 |
| ulcer drug | #148 |
| 0001 corneal | #148 |
| dynamic visual acuity | #148 |
| increased goblet | #148 |
| intraocular lens iol | #149 |
| quantitative evaluation | #149 |
| concentration tacrolimus | #149 |
| fibroblasts production | #149 |
| cationic protein | #149 |
| suspension based | #149 |
| patients allergic | #149 |
| japan phenotype | #149 |
| pyrimidinones treatment | #150 |
| japanese cedar pollen | #150 |
| inflammatory cells | #150 |
| controls performed | #151 |
| inflammation reduction | #151 |
| tacrolimus treated | #152 |
| postoperative secondary | #152 |
| par2 reverse | #152 |
| symptoms objective | #153 |
| increased fibroblasts | #153 |
| artificial tears | #153 |
| induced eotaxin | #153 |
| eyes 11 | #153 |
| 28 surgery | #153 |
| concentrations il4 | #154 |
| grade effects | #155 |
| inflammation ocular | #155 |
| male mitomycin | #155 |
| chemokine expression | #156 |
| eyelids female | #156 |
| alcon | #156 |
| association pm25 | #156 |
| ointments skin | #157 |
| lipid infiltration | #157 |
| greater inflammation | #157 |
| analysis prostaglandin | #157 |
| rates untreated | #157 |
| values improved | #157 |
| inflammatory ocular | #157 |
| pcr increase | #157 |
| acuities | #158 |
| japan included | #158 |
| surface status | #158 |
| trial tacrolimus | #158 |
| immunological characteristics | #159 |
| 3 boys | #159 |
| weeks adverse | #159 |
| study inflammation | #160 |
| elevation study | #161 |
| muc16 | #161 |
| acid schiff | #161 |
| chemokines production | #161 |
| 28 female | #161 |
| thirtysix eyes | #161 |
| mucin 5ac | #161 |
| surgery topical | #162 |
| distance visual acuity | #162 |
| 326 years | #162 |
| male meibomian | #162 |
| bromobenzenes | #162 |
| efficacy tacrolimus | #163 |
| oxidative stress status | #163 |
| prevalence ocular | #163 |
| il1beta il2 | #163 |
| olopatadine | #163 |
| visit 7 | #163 |
| studied 21 | #163 |
| twentynine eyes | #163 |
| steroid anti | #164 |
| 002 treatment | #164 |
| spt positive | #164 |
| patients topical | #164 |
| purpose reported | #164 |
| soft contact | #164 |
| 30ng | #164 |
| biological dressings | #165 |
| production prostaglandin | #165 |
| pgd2 induced | #166 |
| cytometry hla | #166 |
| fluorescein humans | #166 |
| tacrolimus ointment | #167 |
| cytokines allergic | #167 |
| eosinophils higher | #167 |
| males 5 | #168 |
| ulcers erosions | #168 |
| seldi | #169 |
| treating refractory | #169 |
| 12 males | #169 |
| studies tacrolimus | #169 |
| eotaxin chemokine | #169 |
| local allergic | #169 |
| patients postsurgical | #169 |
| steroidal blotting | #169 |
| expression chemokines | #170 |
| management enzyme | #171 |
| conjunctiva conjunctival | #171 |
| status inflammation | #171 |
| subbasal nerve | #172 |
| palisades | #173 |
| fibroblasts fibroblast | #173 |
| subjective symptoms | #174 |
| vivo confocal | #174 |
| slit lamp | #174 |
| pcr flow | #174 |
| distance acuity | #174 |
| standard conventional | #174 |
| status oxidative | #174 |
| postkeratoplasty | #175 |
| 34 eyes | #175 |
| homologous molecule | #176 |
| evaluated symptoms | #176 |
| dust extract | #177 |
| treatment corneal | #177 |
| study longterm outcomes | #177 |
| aldehydes biomarkers | #177 |
| subbasal | #177 |
| mild 2 | #178 |
| strabismus adolescent | #178 |
| tryptase | #178 |
| endophthalmitis female | #178 |
| reduction intraocular pressure | #178 |
| acrysof | #178 |
| risk ocular | #179 |
| chemokine genes | #179 |
| migration eosinophils | #180 |
| japan young adult | #180 |
| myopic regression | #180 |
| 4 female | #180 |
| dyes follow | #180 |
| ceramides child | #180 |
| compared eye | #180 |
| normal control patients | #181 |
| lipid study | #181 |
| cutometer | #181 |
| serum il4 | #183 |
| blepharitis | #183 |
| lipoproteins micafungin | #183 |
| male radioallergosorbent | #184 |
| igg virus | #185 |
| mucin4 mucins | #185 |
| human lymphocyte antigen | #185 |
| examined parameters | #186 |
| nerve prospective | #186 |
| therapy corneal | #186 |
| corneal fibroblasts | #187 |
| efficacy topical | #187 |
| drug fibroblasts humans | #187 |
| suspensions administration | #187 |
| atopic eosinophils | #187 |
| par2 mrna | #187 |
| il13 increased | #188 |
| 19 eyes | #188 |
| corneal sensitivity | #188 |
| eye symptoms | #188 |
| sensitivity regulation | #189 |
| allergic cross | #189 |
| seconds patients | #189 |
| production stromal | #189 |
| levels 33 | #190 |
| infiltrating eosinophils | #191 |
| assisted infrared | #191 |
| effects diesel | #191 |
| tear break | #191 |
| improvement subjective | #192 |
| allergic rhinoconjunctivitis | #193 |
| controls vivo | #193 |
| therapeutic study | #193 |
| 26 eyes | #194 |
| expression rantes | #195 |
| fibroblasts inhibited | #195 |
| reactivation epstein | #195 |
| female histamine | #196 |
| rigid gas | #196 |
| interleukin4 production | #197 |
| methods primary | #197 |
| tear film stability | #197 |
| treatment topical | #197 |
| eyes 21 | #197 |
| 80 allergens | #197 |
| elisa performed | #198 |
| combination topical | #198 |
| 28 eyes | #198 |
| tears time | #198 |
| effects topical | #199 |
| pollen prospective | #199 |
| photorefractive keratectomy | #201 |
| mcp1 ip10 | #201 |
| perennial allergic | #201 |
| preservative free | #201 |
| pollen allergic | #201 |
| rsv infected | #202 |
| unit density | #202 |
| receptor homologous | #202 |
| hypersensitivity interleukin13 | #202 |
| eosinophils neutrophils | #203 |
| ova alum | #204 |
| grade scale | #204 |
| differences iop | #204 |
| vcam1 icam1 | #204 |
| pge2 human | #204 |
| eyes 005 | #205 |
| inflammatory allergic | #205 |
| time tbut | #206 |
| minutes 8 | #206 |
| eyes cataract | #206 |
| disease dry | #206 |
| disease acd | #206 |
| count cornea | #207 |
| pressure lens | #207 |
| ecp levels | #207 |
| formation giant | #207 |
| glands middle | #207 |
| crth2 | #207 |
| size contact | #208 |
| mammalian milk | #208 |
| fluorescein fluorescent | #208 |
| tears aged | #208 |
| analysis pm25 | #209 |
| uncorrected corrected | #209 |
| human allergic | #210 |
| treatment allergic | #210 |
| month reduction | #210 |
| refractory conventional | #211 |
| antiallergic drug | #211 |
| oct diagnosis | #211 |
| inflammation injection | #212 |
| iol patients | #212 |
| tacrolimus combination | #212 |
| combination tests | #212 |
| treated refractory | #213 |
| chamber anti | #213 |
| conjunctiva eye | #213 |
| steroids treatment | #214 |
| muc5ac | #214 |
| alpha il4 | #215 |
| ige higher | #216 |
| allergic agents | #217 |
| conjunctival goblet | #217 |
| worse eyes | #218 |
| lens purpose | #218 |
| nuclear cataract | #219 |
| expressions higher | #219 |
| conjunctival biopsy | #220 |
| august october | #220 |
| metabolism lysine | #220 |
| tranilast | #220 |
| findings inflammation | #221 |
| conjunctivitis acute | #221 |
| combined therapy | #222 |
| samples correlated | #222 |
| twentyfour eyes | #222 |
| diseases dry | #222 |
| cells crth2 | #222 |
| level ambient | #222 |
| iop corneal | #224 |
| symptoms short | #224 |
| 26 control subjects | #224 |
| sensitivity measurements | #224 |
| allergic drug | #225 |
| patients eye | #226 |
| 17 eyes | #227 |
| eyes adult | #228 |
| treatment 3 months | #228 |
| corneal clarity | #228 |
| followup cases | #229 |
| itching | #229 |
| corrected distance | #230 |
| eye signs | #230 |
| treatment superior | #230 |
| 30 eyes | #231 |
| exhaust particles | #231 |
| activity eosinophils | #231 |
| scleral flap | #232 |
| events initiation | #232 |
| alpha defensin | #232 |
| examined level | #232 |
| anti allergic | #233 |
| dye staining | #233 |
| cyclosporine treatment | #233 |
| 791 patients | #233 |
| proteinchip | #233 |
| concomitantly administered | #233 |
| 644 years | #234 |
| examined production | #235 |
| cultured eosinophils | #235 |
| quantitatively evaluate | #236 |
| specimens patients | #236 |
| corneal disease | #236 |
| term topical | #237 |
| gamma transcripts | #237 |
| topical steroid | #238 |
| diagnostic abilities | #240 |
| proliferative lesions | #240 |
| studied subjects | #240 |
| tool quantitative | #240 |
| eyes ocular | #241 |
| bf patients | #241 |
| cell chemotactic | #242 |
| cromolyn sodium | #242 |
| surface lipid | #242 |
| performed higher | #245 |
| common ocular | #245 |
| specular microscopy | #246 |
| equivalent 2 | #247 |
| subjects males | #247 |
| eye drops | #247 |
| specificity cutoff | #248 |
| chemosis | #248 |
| failure visual | #250 |
| labeling intercellular | #251 |
| response prostaglandin | #251 |
| syndrome tears | #252 |
| males 13 | #252 |
| leukocyte child | #252 |
| subjective objective | #252 |
| seasonal allergic | #252 |
| topical oral | #253 |
| levels tacrolimus | #253 |
| improved vision | #255 |
| muc | #255 |
| corneal female | #255 |
| rantes expression | #256 |
| stability positive | #256 |
| dexamethasone inhibition | #256 |
| disease corneal | #257 |
| treating severe | #257 |
| eosinophil chemotaxis | #258 |
| questionnaire objective | #259 |
| tear | #259 |
| role histamine | #260 |
| additional medications | #260 |
| month treatment | #260 |
| eyes control | #260 |
| eosinophil infiltration | #260 |
| human transcription | #261 |
| expression rsv | #261 |
| h1 antagonist | #262 |
| smaller normal | #262 |
| immunohistochemistry increased | #264 |
| severity adverse | #264 |
| aged mucin | #264 |
| 1 month treatment | #264 |
| steroid induced | #265 |
| keratoplasty pkp | #265 |
| controls p0001 | #266 |
| eyelid diseases | #266 |
| signs blood | #267 |
| data weekly | #267 |
| respiratory syncytial virus | #268 |
| microscopy negative | #268 |
| patients sjögren syndrome | #268 |
| studied production | #268 |
| treatment atopic | #268 |
| sodium drug | #269 |
| aged aldehyde | #270 |
| computer terminals | #270 |
| h1 histamine | #270 |
| dry eye symptoms | #271 |
| prevalence allergic | #272 |
| improved visual acuity | #273 |
| aldose reductase inhibitor | #273 |
| 13 males | #273 |
| combination eosinophils | #274 |
| epithelium endothelium | #274 |
| concentration quantitative | #274 |
| studies stevens | #274 |
| meibomian gland dysfunction | #275 |
| patients sjögren | #277 |
| tear breakup time | #277 |
| meibomian gland | #277 |
| grading score | #278 |
| tbut | #278 |
| individuals pcr | #278 |
| bloodaqueous barrier | #279 |
| eyes 14 | #279 |
| 0001 diagnosis | #279 |
| 13 females | #279 |
| interleukin il4 | #280 |
| multifunctional glycoprotein | #280 |
| required provide | #281 |
| 10 seconds | #281 |
| cautery | #282 |
| expressed th2 | #282 |
| disease purpose | #282 |
| ige positive | #284 |
| gland dysfunction | #284 |
| contralateral eye | #285 |
| amniotic membrane | #285 |
| seasons adolescent | #286 |
| atopic | #286 |
| th2 cytokines | #287 |
| layer adult | #288 |
| cases refractory | #288 |
| adult alkylating | #289 |
| study tacrolimus | #289 |
| eyedrops | #291 |
| entericcoated | #291 |
| water child | #292 |
| iop glaucoma | #293 |
| new antifungal | #294 |
| exponential equation | #294 |
| treatment 01 | #294 |
| serum periostin | #295 |
| single therapy | #295 |
| levels ige | #295 |
| surgery statistically | #297 |
| hyperemia | #297 |
| seventy eyes | #299 |
| rose bengal | #300 |
| severity diagnosis | #300 |
| ccl11 chemokine | #300 |
| pkp | #301 |
| benzalkonium chloride | #301 |
| morphologic alterations | #302 |
| cobblestone | #303 |
| assessed based | #303 |
| moderate 3 | #303 |
| photophobia | #304 |
| scanning laser | #304 |
| initiation treatment | #305 |
| operation patient | #305 |
| scores worse | #305 |
| eczema severity | #306 |
| piperidines treatment | #306 |
| assessed 4 | #307 |
| membrane patch | #307 |
| gel application | #308 |
| interleukin13 interleukin2 | #309 |
| evaluation groups | #309 |
| 10 normal subjects | #309 |
| compared simple | #310 |
| inflammatory cell | #310 |
| comfort level | #310 |
| cytology specimens | #311 |
| regard age | #311 |
| slitlamp examination | #311 |
| treatment seasonal | #311 |
| 12 eyes | #311 |
| 7 eyes | #312 |
| molecules chronic | #313 |
| eye adult | #315 |
| aged staining | #315 |
| 19 normal | #316 |
| child corneal | #316 |
| interferometry light | #317 |
| cells cornea | #317 |
| analysis glaucoma | #318 |
| values lower | #319 |
| prospective singlearm study | #320 |
| dermatitis clinical | #320 |
| fluorophotometry | #320 |
| il8 rantes | #321 |
| cells chemotaxis | #321 |
| bilateral cataracts | #323 |
| ulcers | #323 |
| pollen allergen | #324 |
| agreement weighted | #324 |
| 15 30 minutes | #325 |
| eyes 19 | #325 |
| icam1 vcam1 expression | #326 |
| 095 ± | #326 |
| surgery diabetic | #327 |
| chemokine concentrations | #327 |
| transplantation corneal | #328 |
| expression goblet | #329 |
| icam1 antibody | #329 |
| insensible | #330 |
| treatment 2 weeks | #331 |
| pressure ocular | #331 |
| receptors il2r | #332 |
| dry eye disease | #332 |
| leukocyte coculture | #333 |
| eye treated | #335 |
| values daily | #335 |
| cornea diagnostic | #335 |
| proprietary | #336 |
| 27 eyes | #337 |
| male staphylococcal | #337 |
| corneal epithelial | #337 |
| daily wear | #339 |
| signs clinical | #339 |
| eyes 27 | #341 |
| levels epithelial | #341 |
| methods eyes | #342 |
| asthenopia | #343 |
| illness tacrolimus | #344 |
| limbus | #346 |
| measurements treatment | #347 |
| corneal infection | #347 |
| eyes 13 | #348 |
| induced elevation | #348 |
| expression eosinophils | #348 |
| test values | #350 |
| surgery eye | #350 |
| contrast visual | #352 |
| surface diseases | #352 |
| iop elevation | #353 |
| weekly average | #354 |
| expression allergic | #354 |
| incidence allergic | #355 |
| temperature infrared | #355 |
| choroidal detachment | #356 |
| examination serum | #356 |
| tear film | #357 |
| patients allergy | #357 |
| local cytokine | #358 |
| eyes 8 | #358 |
| months conventional | #359 |
| tacrolimus tumor | #359 |
| difference efficacy | #361 |
| subjects 13 | #361 |
| agents benzophenones | #362 |
| aureus patients | #363 |
| messenger blotting | #363 |
| injections lidocaine | #364 |
| studies sclera | #368 |
| function laser | #368 |
| plant pollen | #368 |
| treatment ocular | #368 |
| corneae male | #369 |
| postoperative adhesion | #370 |
| mucin1 mucin2 | #370 |
| eyes 17 | #370 |
| systemic control | #371 |
| inhibitors epithelium | #372 |
| cryptomeria japonica | #372 |
| sixteen eyes | #373 |
| micafungin middle | #374 |
| periodic acid schiff | #374 |
| assessment severe | #375 |
| improvement local | #375 |
| cornea female | #375 |
| extraction cell | #376 |
| retina tomograph | #376 |
| phacoemulsification prospective | #377 |
| 4 lower | #377 |
| higher human | #377 |
| 10 normal | #377 |
| levels atopic | #377 |
| tarsal | #378 |
| treatment eyes | #378 |
| count child | #378 |
| stimulation tnf | #380 |
| mitomycin | #380 |
| cornea eye | #381 |
| corneal inflammation | #381 |
| negative serum | #382 |
| pollinosis | #383 |
| inflammation epithelial | #383 |
| examinations including | #384 |
| gas permeable | #384 |
| vivo corneal | #385 |
| corneal epithelial cells | #386 |
| ocular diseases | #386 |
| surgery 13 | #388 |
| limit assay | #388 |
| surface alterations | #388 |
| decrease inflammatory | #388 |
| healing adult | #389 |
| cells vehicle | #389 |
| severity incidence | #390 |
| sde | #390 |
| antiallergic | #391 |
| patients proteins | #391 |
| breakup time | #393 |
| immunohistochemistry tests | #394 |
| applied 5 | #395 |
| chronic ocular | #395 |
| 44 eyes | #395 |
| techniques interleukin4 | #396 |
| relative percentages | #396 |
| opacity corneal | #396 |
| apparatus lacrimal | #397 |
| expression lower | #397 |
| increased understanding | #398 |
| ocular surface disease | #399 |
| pressure elevation | #399 |
| declaration helsinki | #400 |
| remission based | #400 |
| eyes severe | #401 |
| modified boyden | #401 |
| rays male | #402 |
| sedating humans | #403 |
| weather air | #404 |
| cells allergic | #404 |
| vogt | #404 |
| measurements oct | #404 |
| prospective controlled study | #405 |
| reproducibility surface | #406 |
| patients epithelial | #406 |
| improved diagnosis | #407 |
| 137 years | #407 |
| serum total ige | #407 |
| postoperative aged | #408 |
| activated fibroblasts | #409 |
| heidelberg retina tomograph | #410 |
| specific total | #412 |
| confocal | #412 |
| eyes 15 | #412 |
| acids fibroblasts | #412 |
| allergic reaction | #413 |
| 3 months treatment | #413 |
| counts 1 | #413 |
| keratocytes | #414 |
| limbal | #416 |
| postoperative inflammation | #416 |
| central cornea | #418 |
| penetrating keratoplasty | #418 |
| patients comfort | #419 |
| speed resolution | #419 |
| chemokine ccl11 | #419 |
| mucin4 | #419 |
| sjögren syndrome | #420 |
| ophthalmologist | #420 |
| lacrimal gland | #422 |
| 20 normal controls | #424 |
| 40 minutes | #425 |
| clinical observation | #425 |
| production 4 | #430 |
| trabeculectomy visual | #430 |
| rhinoconjunctivitis | #431 |
| staining score | #431 |
| 0 normal | #433 |
| subjects atopic | #434 |
| performed immunohistochemistry | #437 |
| cedrus | #437 |
| 5 women | #438 |
| methods eye | #438 |
| regulation eye | #438 |
| commercial tests | #439 |
| interleukin4 il4 | #440 |
| subjects studied | #440 |
| foldable | #440 |
| fluorescein dye | #441 |
| regulation chemokine | #441 |
| vmr | #441 |
| landolt | #441 |
| adult aldehydes | #442 |
| females normal | #442 |
| anti vcam1 | #442 |
| 17 males | #444 |
| male mucin1 | #444 |
| patients combined therapy | #445 |
| 39 consecutive patients | #447 |
| dogs dust | #448 |
| air pollution data | #448 |
| 30 serum | #450 |
| male 4 | #450 |
| eye eyes | #451 |
| wash | #452 |
| keratoplasty | #452 |
| versus vehicle | #453 |
| antagonists sedating | #453 |
| ketotifen | #453 |
| response allergens | #454 |
| surface disorder | #454 |
| normal patients | #454 |
| vivo confocal microscopy | #454 |
| 8 genes | #455 |
| ophthalmic nerve | #455 |
| production clearance | #455 |
| water evaporation | #455 |
| agonists pilocarpine | #456 |
| humans keratoplasty | #456 |
| ocular risk | #457 |
| amnion cell | #457 |
| normal controls patients | #457 |
| outpatient visits | #457 |
| checker | #459 |
| oct study | #460 |
| greatest improvements | #461 |
| distance visual | #461 |
| test evaluation | #462 |
| keratoplasty penetrating | #462 |
| hel | #466 |
| fibroblasts tgf | #467 |
| unpaired ttest | #467 |
| study pcr | #468 |
| background atopic | #469 |
| examination diagnosis | #469 |
| major sources | #470 |
| markers severity | #473 |
| allergy adult | #473 |
| metry | #475 |
| diagnosis rate | #476 |
| hladr expression | #476 |
| 13 mmhg | #478 |
| pollen seasons | #478 |
| fibroblasts primary | #478 |
| newly formed vessels | #480 |
| height measurement | #480 |
| reduce clinical | #480 |
| subjects eyes | #481 |
| interleukin 13 | #482 |
| examined prospective | #482 |
| crystalline lens implantation | #485 |
| 21 eyes | #488 |
| accommodating | #488 |
| induced 15 | #489 |
| shortterm study | #490 |
| myopia photorefractive | #490 |
| disodium cromoglycate | #493 |
| prolonged inflammation | #495 |
| ebv reactivation | #495 |
| acuity intraocular | #495 |
| months eyes | #498 |
| corneal | #498 |
| exposure diesel | #499 |
| stain positive | #499 |
| il2 tumor | #499 |
| lens iol | #500 |
| silicone hydrogel | #500 |
| infections viral | #501 |
| symptoms efficacy | #501 |
| treatment eye | #502 |
| pge2 cox2 | #502 |
| studies status | #502 |
| heidelberg retina | #503 |
| 42 eyes | #504 |
| 2 daily | #505 |
| eye position | #505 |
| inflammatory status | #506 |
| airborne particulate matter | #506 |
| correlate severity | #506 |
| penetrating male | #507 |
| aldose reductase | #509 |
| induced ocular | #509 |
| 1 mild | #511 |
| cats child | #512 |
| treatment visual | #514 |
| 45 subjects | #516 |
| topical | #516 |
| disposable equipment | #517 |
| inhibition production | #519 |
| male water | #519 |
| observed baseline | #519 |
| groups duration | #520 |
| lipopeptides lipoproteins | #520 |
| 01 | #522 |
| chemoattractant receptor | #522 |
| metaregression analysis | #523 |
| 10 normal volunteers | #524 |
| infection rsv | #524 |
| dinoprostone epithelial | #525 |
| studies trabeculectomy | #525 |
| studies cornea | #527 |
| trabeculectomy | #527 |
| density basal | #528 |
| giemsa staining | #528 |
| rhodanine | #531 |
| itchy | #531 |
| ocular symptoms | #535 |
| serum antigen | #535 |
| 44yearold | #536 |
| purpose case | #537 |
| total hydrocarbons | #538 |
| patients cataract | #538 |
| sac | #539 |
| dependent migration | #539 |
| placebo tablets | #540 |
| capsular bag | #540 |
| 80 anterior | #541 |
| visit 6 | #541 |
| cases flow | #542 |
| administration topical | #542 |
| infrared radiation | #543 |
| 20 normal | #543 |
| 6 male | #544 |
| ebv nuclear antigen | #546 |
| production cultured | #546 |
| time improved | #547 |
| periodic acid | #549 |
| pollution allergens | #549 |
| prospective comparative study | #550 |
| film layer | #550 |
| cryptomeria | #552 |
| il‐4 | #552 |
| disease complicated | #553 |
| effects cooling | #553 |
| engorgement | #554 |
| disease ded | #555 |
| fibroblasts response | #555 |
| genechip | #555 |
| setting department | #556 |
| noninfected cells | #557 |
| density assessed | #558 |
| transplantation combined | #558 |
| diesel exhaust particles | #559 |
| methods thirty | #559 |
| ocular infections | #560 |
| differentiation inflammatory | #560 |
| eyes iop | #560 |
| eyes 24 | #562 |
| laser trabeculoplasty | #562 |
| positive 30 | #563 |
| 16 age | #569 |
| count corneal | #569 |
| levels il4 | #570 |
| cultured corneal | #570 |
| meibomian | #572 |
| female humans specificity | #576 |
| allergen challenge | #577 |
| corneal diseases | #578 |
| iop eyes | #580 |
| 4 mrna | #580 |
| lesions normal | #582 |
| apparatus male | #582 |
| fibrosis fluorescent | #582 |
| department ophthalmology | #584 |
| tnfalpha stimulation | #584 |
| increase vegf | #584 |
| symptoms scores | #588 |
| hladr antigen | #589 |
| female humans allergic | #589 |
| intraocular male | #589 |
| patients csa | #589 |
| induced 4 | #589 |
| corneal epithelium | #589 |
| study lipid | #590 |
| diseases regulation | #591 |
| icam1 vcam1 | #592 |
| cytological techniques | #593 |
| observed real | #595 |
| findings evaluated | #597 |
| assay eye | #597 |
| epithelium corneal | #598 |
| cells chemokine | #599 |
| diesel exhaust | #602 |
| cornea epithelium | #603 |
| mrna tgf | #604 |
| thermometer | #605 |
| grading scale | #606 |
| inflammation status | #609 |
| topical adult | #609 |
| corneal nerves | #611 |
| thermography | #611 |
| eosinophils epithelial | #612 |
| fluorescent dyes humans | #613 |
| synergic | #614 |
| antagonists humans | #615 |
| patients complained | #615 |
| cells oligopeptides | #616 |
| diagnosis type | #616 |
| ocular allergy | #617 |
| grades 0 | #617 |
| flaps suture | #618 |
| subjects conclusion | #621 |
| il4 | #623 |
| years studied | #625 |
| lamp examination | #625 |
| glaucoma medications | #625 |
| ophthalmologists | #626 |
| occlusion treatment | #628 |
| micafungin | #635 |
| burning sensation | #636 |
| corneal haze | #636 |
| patients tacrolimus | #636 |
| redness | #636 |
| total immunoglobulin | #638 |
| based severity | #639 |
| contact lenses | #639 |
| eosinophils | #639 |
| male rhinitis | #640 |
| 511 patients | #640 |
| development allergic | #641 |
| 11 eyes | #641 |
| symptoms signs | #643 |
| performed modified | #643 |
| months 01 | #643 |
| observed follow | #644 |
| fibrosis actins | #645 |
| mellitus double | #645 |
| patients healthy volunteers | #650 |
| expression administration | #651 |
| viscosupplements | #651 |
| 2 females | #651 |
| analysis existence | #654 |
| eosinophils flow | #654 |
| diseases methods | #656 |
| comfortable | #657 |
| lacrimal | #657 |
| patients elisa | #660 |
| nerve density | #661 |
| 96well plate | #661 |
| chamber technique | #662 |
| treatment 0001 | #664 |
| lens wearers | #664 |
| acuity measured | #665 |
| molecule1 cell | #668 |
| damage scores | #669 |
| 10 age | #669 |
| viruses acute | #669 |
| stimulation rna | #672 |
| cedar | #672 |
| 11 males | #673 |
| humans lacrimal | #673 |
| scleritis | #677 |
| levels correlation | #678 |
| administration ophthalmic | #680 |
| test methods | #681 |
| adherence anti | #681 |
| antibody negative | #682 |
| chemokine gene | #683 |
| stainings | #684 |
| fibronectin cell | #684 |
| single visit | #685 |
| goblet | #686 |
| cells collected | #688 |
| differential diagnosis patients | #689 |
| visual acuity patients | #690 |
| atopic female humans | #694 |
| cells eye | #694 |
| 1 test | #695 |
| early antigen | #697 |
| inhibition expression | #697 |
| levels detection | #700 |
| objective assessments | #700 |
| cromolyn | #700 |
| intraocular inflammation | #703 |
| eyelid | #704 |
| labeling surface | #705 |
| antineoplastic child | #707 |
| participants eyes | #709 |
| pain baseline | #711 |
| allergens child | #712 |
| fibroblasts flow | #715 |
| 1 month | #715 |
| major characteristic | #717 |
| 5 eyes | #718 |
| key cells | #718 |
| dibenzazepines | #719 |
| preventing recurrence | #721 |
| production vascular | #722 |
| 088 ± | #724 |
| 32 eyes | #724 |
| promising treatment strategy | #725 |
| squamous metaplasia | #729 |
| aged ophthalmology | #730 |
| 11 male | #730 |
| followup treatment | #730 |
| cytology patients | #731 |
| eyes underwent | #733 |
| pollution data | #735 |
| suppressive effects | #736 |
| symptoms 5 | #737 |
| reductase inhibitor | #737 |
| intraocular lens | #740 |
| keratectomy | #741 |
| density compared | #741 |
| expression real | #744 |
| blood eosinophils | #746 |
| definition classification | #746 |
| unpaired test | #746 |
| inflammation lipid | #748 |
| purpose hypothesis | #749 |
| daily weather | #751 |
| cornea corneal | #751 |
| interleukin13 male | #752 |
| fibroblasts cultured | #754 |
| eyes 6 | #758 |
| iol implantation | #759 |
| follow cases | #759 |
| allergens anti | #762 |
| intraocular lens implantation | #763 |
| trabeculectomy treatment | #763 |
| topical aged | #763 |
| 148 years | #764 |
| drugs primary | #765 |
| aged chemokine | #766 |
| oligopeptides rna | #769 |
| pathogenesis severe | #769 |
| measurements improved | #772 |
| pge2 production | #775 |
| eotaxin | #776 |
| cells adolescent | #782 |
| role allergic | #783 |
| levels prostaglandin | #783 |
| limbus corneae | #784 |
| fluorescein fluoresceins | #784 |
| blinking | #785 |
| treatment 1 | #785 |
| purpose analyze | #785 |
| elevated levels | #789 |
| allergic disease | #790 |
| eyes normal | #792 |
| lenses intraocular | #792 |
| techniques laminin | #793 |
| tacrolimus | #793 |
| increased epithelial | #793 |
| ocular inflammation | #794 |
| 4 hne | #794 |
| months visual | #798 |
| treatment p0001 | #800 |
| positive linear | #801 |
| report efficacy | #801 |
| radioallergosorbent | #802 |
| excimer male | #804 |
| cells western | #806 |
| receptors ccr3 | #813 |
| mucin | #813 |
| 21 individuals | #814 |
| brush | #816 |
| acuity adolescent | #817 |
| biomicroscopy | #819 |
| concentration dose | #820 |
| aged cell | #820 |
| cells eosinophils | #821 |
| interleukin4 | #821 |
| phenotype practice | #822 |
| temperature case | #825 |
| year adolescent | #831 |
| lymphocytes compared | #834 |
| preoperative level | #834 |
| cases follow | #835 |
| surgical outcome | #835 |
| pachymetry | #840 |
| individuals patients | #841 |
| patients operation | #841 |
| implantation intraocular | #842 |
| ocular adolescent | #843 |
| symptoms improved | #843 |
| elevated iop | #845 |
| new surgical technique | #845 |
| levels air | #848 |
| 2 weeks treatment | #848 |
| exhaust | #848 |
| loss insensible | #851 |
| fluorescein | #853 |
| purpose prospectively | #855 |
| cell area | #855 |
| 10 eyes | #858 |
| methane hydrocarbons | #860 |
| inhibitors diclofenac | #861 |
| myopic eyes | #861 |
| histamine h1 | #865 |
| thiazolidines | #865 |
| thirteen cases | #866 |
| patients ocular | #867 |
| test kits | #868 |
| serum antibody titers | #872 |
| patients eyes | #874 |
| 01 compared | #874 |
| dry eyes | #876 |
| mitomycinc | #878 |
| syndrome sjs | #879 |
| h1 antagonists | #880 |
| benzamidine | #880 |
| evaluation early | #880 |
| patient comfort | #881 |
| assessing efficacy | #882 |
| cells contributes | #882 |
| diseases background | #883 |
| study eye | #886 |
| patients condition | #887 |
| bleb | #887 |
| specular | #890 |
| 114 years | #894 |
| respiratory syncytial | #894 |
| age eye | #895 |
| noncomparative | #897 |
| pain inflammation | #901 |
| ocular | #902 |
| levels pm25 | #903 |
| 20 eyes | #904 |
| decreased baseline | #905 |
| benzophenones | #905 |
| circulating autoantibodies | #907 |
| clinical signs | #910 |
| examined pcr | #911 |
| lacrimal duct | #911 |
| aureus young | #912 |
| gauze | #917 |
| corneae | #919 |
| sjögren | #920 |
| immunoglobulin immunosuppressive | #921 |
| 10 females | #925 |
| treatment symptoms | #928 |
| 8 males | #928 |
| immunoregulatory effects | #929 |
| epithelial lesions | #929 |
| histopathologic analysis | #930 |
| disease efficacy | #932 |
| ophthalmologic surgical | #933 |
| normal controls | #933 |
| beta1 tumor | #937 |
| epithelialization | #937 |
| iop measured | #939 |
| treatment severe | #940 |
| symptoms evaluated | #941 |
| cytokines epithelial | #941 |
| normal 1 | #943 |
| factor production | #946 |
| humans muscarinic | #946 |
| wheal | #947 |
| radioallergosorbent test | #949 |
| mgd | #949 |
| humans lenses | #950 |
| seasons young | #950 |
| ulcer humans | #952 |
| sensitivity values | #953 |
| 2 moderate | #957 |
| scanning confocal | #957 |
| 3 eyes | #959 |
| aldose | #959 |
| singleagent therapy | #959 |
| endpoint baseline | #960 |
| intracellular infection | #961 |
| sedating | #961 |
| expression 8 | #962 |
| dust mites | #963 |
| observed 3 | #965 |
| eyes 12 | #966 |
| ecp | #967 |
| total score | #968 |
| expression chemokine | #969 |
| positively stained | #971 |
| term therapeutic | #973 |
| basal epithelial | #973 |
| mcp1 gene | #980 |
| day month | #981 |
| 6 males | #983 |
| detected patients | #985 |
| ointment | #989 |
| 4 regulation | #990 |
| primary cultured | #992 |
| carried patients | #993 |
| observed conclusions | #994 |
| tenon | #994 |
| technique 2 | #998 |
| adult cornea | #1001 |
| observed vivo | #1002 |
| methods sixteen | #1002 |
| serum ige | #1005 |
| pediatric subjects | #1008 |
| accommodation ocular | #1009 |
| boyden | #1011 |
| eye infections | #1012 |
| time year | #1012 |
| piperidines pyridines | #1013 |
| allergic diseases | #1014 |
| 1 2 weeks | #1017 |
| blink | #1017 |
| normal volunteers | #1019 |
| impression | #1019 |
| improved 1 | #1020 |
| cells positively | #1021 |
| ω3 fatty acids | #1024 |
| model allergic | #1028 |
| studied prospectively | #1029 |
| induced chemotaxis | #1031 |
| diopter | #1032 |
| improved 3 | #1033 |
| 2 eyes | #1036 |
| patching | #1040 |
| 045 ± | #1040 |
| webbased questionnaire | #1040 |
| chemotaxis | #1042 |
| values analysis | #1043 |
| cells fibroblasts | #1044 |
| lysine 4 | #1044 |
| treatment skin | #1045 |
| concomitantly | #1045 |
| xerophthalmia | #1046 |
| indirect humans | #1050 |
| recurrence 6 | #1050 |
| allergen extracts | #1053 |
| symptoms score | #1054 |
| johnson syndrome | #1057 |
| eyelids | #1059 |
| study therapeutic | #1060 |
| allograft transplantation | #1062 |
| guidelines clinical | #1064 |
| giemsa | #1065 |
| staphylococcal enterotoxin | #1067 |
| pollution risk | #1067 |
| disposable | #1067 |
| noninfectious | #1070 |
| acuity patients | #1071 |
| goblet cell | #1071 |
| immunocytochemical study | #1073 |
| effective treating | #1075 |
| months corrected | #1075 |
| eyes received | #1076 |
| efficacy treatment | #1077 |
| benzamidines | #1079 |
| techniques ophthalmological | #1080 |
| ade | #1080 |
| syncytial virus | #1080 |
| expression icam1 | #1082 |
| allergic inflammatory | #1082 |
| sex matched | #1088 |
| cyclosporine patients | #1091 |
| ige anti | #1098 |
| corrected visual acuity | #1099 |
| assessed vivo | #1104 |
| diseases objective | #1104 |
| endothelium corneal | #1107 |
| 10 males | #1109 |
| meibomian glands | #1110 |
| rose | #1116 |
| lens capsule | #1116 |
| 30 patients | #1118 |
| drops | #1121 |
| keratopathy | #1121 |
| popularization | #1122 |
| 92 years | #1122 |
| periostin | #1125 |
| epithelium female | #1132 |
| assay fibroblasts | #1133 |
| treatment objective | #1133 |
| cultures human | #1133 |
| clinical findings | #1133 |
| anti icam1 | #1134 |
| evaluate therapeutic | #1136 |
| controls examined | #1137 |
| healthy eyes | #1140 |
| visual acuities | #1140 |
| prospective controlled | #1141 |
| small incision | #1143 |
| 4 daily | #1146 |
| p0035 | #1146 |
| minimum angle | #1149 |
| aphakic | #1150 |
| aged phacoemulsification | #1153 |
| cyclosporine humans | #1154 |
| interventional case | #1157 |
| airborne particulate | #1165 |
| purpose evaluate | #1171 |
| sjögrens syndrome | #1171 |
| glands sjogren | #1173 |
| cornea | #1173 |
| ophthalmological female | #1189 |
| immune mechanisms | #1189 |
| fibronectins fibrosis | #1189 |
| levels chemokines | #1191 |
| adult dermatitis | #1191 |
| spatial temporal resolution | #1193 |
| cytokine mrna | #1195 |
| refractory standard | #1207 |
| ded | #1209 |
| 84 ± | #1210 |
| concentrations alpha | #1210 |
| 18 females | #1211 |
| boyden chamber | #1212 |
| lasers excimer | #1215 |
| bengal | #1217 |
| scl | #1219 |
| stevens johnson | #1220 |
| par2 | #1222 |
| 025 | #1223 |
| mmc | #1230 |
| microscopy confocal | #1231 |
| allergic inflammation | #1233 |
| instilled | #1235 |
| correlation clinical | #1240 |
| wearers | #1241 |
| eyes treated | #1242 |
| muc5ac expression | #1249 |
| supply adult | #1254 |
| molecule expressed | #1265 |
| messenger reverse | #1266 |
| levels pge2 | #1270 |
| tomograph | #1271 |
| 4 normal | #1274 |
| period clinical | #1275 |
| anesthesia local | #1278 |
| aged substance | #1286 |
| study eyes | #1286 |
| 169 ± | #1287 |
| lacrimal apparatus | #1288 |
| dermatitis atopic | #1289 |
| phacoemulsification | #1290 |
| iol | #1294 |
| cac | #1300 |
| adult antibiotics | #1301 |
| controls 005 | #1302 |
| dryness | #1303 |
| photorefractive | #1304 |
| spring autumn | #1307 |
| intraocular lenses | #1308 |
| japanese cedar | #1310 |
| thermometry | #1311 |
| allergic | #1314 |
| chemokines chemotaxis | #1316 |
| higher severe | #1316 |
| corneal humans | #1317 |
| presence increased | #1318 |
| child chromatography | #1321 |
| expressed secreted | #1321 |
| 830 | #1322 |
| ccl11 | #1322 |
| membrane increased | #1331 |
| treatment improvements | #1334 |
| prostaglandin production | #1335 |
| light lipid | #1337 |
| ccr3 receptors | #1340 |
| fivepoint scale | #1341 |
| operation patients | #1343 |
| ped | #1348 |
| treatment 14 | #1353 |
| antigen child | #1360 |
| benzalkonium | #1365 |
| responses peripheral | #1371 |
| cytokines dinoprostone | #1374 |
| atopic diseases | #1377 |
| 00001 lower | #1383 |
| timeseries analysis | #1384 |
| ointments | #1396 |
| female glucocorticoids | #1399 |
| 18 eyes | #1399 |
| respiratory pathogen | #1404 |
| epithelial barrier function | #1407 |
| proteaseactivated receptor | #1413 |
| diseases diagnosis | #1413 |
| adult allergens | #1414 |
| normal adults | #1416 |
| 005 1 | #1419 |
| 1 week | #1425 |
| prospective comparative | #1428 |
| higher contrast | #1431 |
| patients cgvhd | #1432 |
| rast | #1434 |
| factors seasons | #1439 |
| haze | #1444 |
| corneal neovascularization | #1444 |
| temperature cell | #1445 |
| reduced 1 | #1451 |
| goblet cells | #1451 |
| macular oedema | #1453 |
| histocytological | #1458 |
| corneal opacity | #1465 |
| lens implantation | #1469 |
| complained | #1470 |
| production il4 | #1481 |
| outcome administration | #1488 |
| corneal edema | #1489 |
| data daily | #1497 |
| 2 minutes | #1498 |
| detected frequently | #1499 |
| western cells | #1499 |
| male metaplasia | #1500 |
| studies suture | #1502 |
| bulbar | #1502 |
| pgd2 | #1505 |
| human corneal | #1507 |
| ophthalmological | #1510 |
| staining | #1514 |
| female fluorescein | #1514 |
| 40 mmhg | #1522 |
| studies glaucoma | #1524 |
| total scores | #1526 |
| eosinophils female | #1527 |
| acuity adult | #1530 |
| inhibitors child | #1533 |
| cells density | #1537 |
| 7 females | #1541 |
| production primary | #1542 |
| cytometric analysis | #1544 |
| dioxide particulate | #1548 |
| virus rsv | #1553 |
| pollen rhinitis | #1559 |
| decreased treatment | #1560 |
| steroidal cell | #1566 |
| aged allergens | #1571 |
| fibronectin laminin | #1573 |
| cells 001 | #1575 |
| 15 females | #1580 |
| purpose investigate | #1581 |
| fibroblasts | #1583 |
| effective long | #1589 |
| assessed quantitative | #1591 |
| aldehyde reductase | #1597 |
| preservative | #1602 |
| ortho aminobenzoates | #1602 |
| cells 0001 | #1603 |
| vdt | #1624 |
| humans intraocular | #1624 |
| incidence adverse events | #1625 |
| weeks administration | #1629 |
| eye | #1630 |
| cyclosporine female | #1637 |
| epstein‐barr virus | #1638 |
| epsteinbarr virus ebv | #1641 |
| mitomycin mmc | #1643 |
| preschool dermatitis | #1644 |
| capsule crystalline | #1654 |
| subjects examined | #1658 |
| prevalence severe | #1662 |
| syncytial | #1663 |
| 10 healthy controls | #1663 |
| reaction young | #1665 |
| damage patients | #1666 |
| function small | #1670 |
| infections fungal | #1673 |
| higher normal | #1674 |
| 2 cytokine | #1685 |
| pm25 levels | #1686 |
| dose equivalent | #1687 |
| confocal middle | #1698 |
| 7 males | #1711 |
| outcome visual | #1713 |
| disease defined | #1713 |
| subjects adolescent | #1716 |
| whitney test | #1721 |
| 744 | #1725 |
| topical application | #1735 |
| cytology | #1741 |
| central corneal | #1741 |
| treatment short | #1742 |
| severity treatment | #1754 |
| years 19 | #1754 |
| antigen anti | #1756 |
| iols | #1760 |
| rsv infection | #1761 |
| eightysix patients | #1764 |
| oral steroids | #1775 |
| inflammation assessed | #1779 |
| enterotoxins female | #1789 |
| alpha sma | #1798 |
| mild cases | #1802 |
| 10 healthy | #1811 |
| endophthalmitis eye | #1815 |
| punctate | #1817 |
| antifungal treatment | #1821 |
| receptor par2 | #1823 |
| japan methods | #1823 |
| regulated activation | #1825 |
| sjs | #1827 |
| eosinophil | #1828 |
| 15 minutes | #1828 |
| child dermatitis | #1832 |
| mediator release | #1835 |
| epithelial damage | #1835 |
| factor tnfalpha | #1836 |
| fibroblasts normal | #1837 |
| corneal transplantation | #1838 |
| degrees 4 | #1839 |
| eye examination | #1840 |
| prostaglandin receptors | #1841 |
| inflammation injections | #1842 |
| month 3 | #1846 |
| effects aged | #1848 |
| receptors prostaglandin | #1853 |
| ulcer female | #1857 |
| 005 differences | #1858 |
| comparative evaluation | #1860 |
| shield | #1860 |
| ari | #1862 |
| tnfalpha production | #1862 |
| humans immunosuppressive | #1874 |
| surgery purpose | #1890 |
| aphakia | #1893 |
| cataract surgery | #1893 |
| ige production | #1900 |
| cells epithelial | #1909 |
| sterilized | #1912 |
| interleukin 4 | #1920 |
| ihc staining | #1923 |
| mast cell degranulation | #1929 |
| contact female | #1935 |
| contribute pathogenesis | #1942 |
| 013 ± | #1943 |
| protein female | #1946 |
| severe persistent | #1946 |
| patients exhibited | #1947 |
| score clinical | #1961 |
| vcam1 expression | #1962 |
| 9 males | #1970 |
| 5 minutes | #1970 |
| 4 males | #1971 |
| device treatment | #1972 |
| comfort | #1972 |
| corrected visual | #1974 |
| gpc | #1974 |
| month 1 | #1975 |
| intraocular | #1977 |
| nonuse | #1979 |
| eyes | #1980 |
| controls p005 | #1984 |
| females age | #1990 |
| studies cell | #1992 |
| irritation | #1994 |
| bak | #1999 |
| reaction serine | #2013 |
| diseases diagnostic | #2014 |
| erosions | #2016 |
| agents male | #2023 |
| tacrolimus adult | #2023 |
| surgery 1 | #2025 |
| ccl5 chemokines | #2026 |
| chemotaxis leukocyte | #2031 |
| increased vegf | #2036 |
| treated eyes | #2038 |
| coherence treatment | #2038 |
| based incidence | #2048 |
| eye female | #2049 |
| corneal topography | #2066 |
| ambient air pollution | #2067 |
| versus normal | #2067 |
| allergens animals | #2067 |
| pollen | #2068 |
| dexamethasone enzyme | #2073 |
| herpetic | #2075 |
| temperature measured | #2078 |
| cytokines enzyme | #2084 |
| ophthalmologic | #2091 |
| cytokines dose | #2093 |
| therapeutic effects | #2106 |
| aged antifungal | #2107 |
| activation normal | #2108 |
| clinical examinations | #2112 |
| cultured chemokine | #2118 |
| average concentrations | #2119 |
| acd | #2127 |
| reaction statistics | #2128 |
| human α | #2132 |
| docosahexaenoic acid | #2137 |
| endopeptidases serine | #2137 |
| mucin2 | #2140 |
| antibody positive | #2142 |
| vegf production | #2143 |
| incidence adverse | #2148 |
| scored | #2157 |
| controls 0001 | #2158 |
| expression patient | #2160 |
| umin | #2163 |
| production inhibited | #2164 |
| curve reproducibility | #2164 |
| virus human | #2170 |
| study flow | #2171 |
| density lower | #2174 |
| pressure iop | #2177 |
| sensation | #2181 |
| dyes humans | #2183 |
| adult administration | #2184 |
| regulation adolescent | #2185 |
| eyes patients | #2186 |
| eye disease | #2190 |
| child computer | #2191 |
| diseases female | #2192 |
| aged mitomycin | #2192 |
| duct obstruction | #2202 |
| pseudophakic | #2208 |
| ulcer patients | #2219 |
| cases severe | #2231 |
| greater concentrations | #2232 |
| 1 3 months | #2234 |
| immunoglobulin male | #2235 |
| upper lower | #2236 |
| matter pm25 | #2243 |
| rater agreement | #2246 |
| vital | #2246 |
| scores correlated | #2247 |
| pollens | #2247 |
| allergic seasonal | #2250 |
| groups difference | #2250 |
| tryptases | #2264 |
| compared vehicle | #2265 |
| individuals adolescent | #2270 |
| myopic | #2271 |
| slit | #2275 |
| il4 il13 | #2279 |
| exposure particulate | #2280 |
| uncorrected | #2284 |
| studies stem | #2285 |
| 6 months | #2290 |
| diseases enzyme | #2294 |
| cooling | #2297 |
| female gels | #2302 |
| humans hypersensitivity | #2311 |
| clinical appearance | #2312 |
| topical treatment | #2312 |
| rsv | #2316 |
| performed treatment | #2323 |
| animal study | #2332 |
| hours dose | #2336 |
| il4 production | #2339 |
| culture supernatants | #2343 |
| weeks 1 | #2344 |
| mann whitney | #2351 |
| ca125 antigen | #2354 |
| method assessing | #2371 |
| syncytial viruses | #2377 |
| skin adolescent | #2378 |
| treatment 2 | #2392 |
| immunosuppressive agents | #2409 |
| relieving | #2410 |
| months initiation | #2412 |
| ophthalmology | #2415 |
| aged nitrogen | #2415 |
| child enzyme | #2420 |
| stevens | #2422 |
| effective patients | #2424 |
| intraocular pressure | #2425 |
| prostaglandin | #2433 |
| interleukin2 receptors | #2456 |
| transcription levels | #2459 |
| sclera | #2464 |
| glaucoma humans | #2492 |
| ige antibody | #2493 |
| enteric coated | #2498 |
| fungal female | #2498 |
| diseases adolescent | #2503 |
| scores clinical | #2510 |
| obstruction male | #2513 |
| histamine | #2514 |
| h1 receptor | #2516 |
| histamine humans | #2533 |
| humans hyperemia | #2535 |
| levels alpha | #2543 |
| ebv | #2546 |
| patients symptoms | #2550 |
| cell expressed | #2557 |
| correlated severity | #2565 |
| oct | #2571 |
| methods clinical | #2571 |
| flare | #2573 |
| male polymerase | #2573 |
| controls serum | #2578 |
| penetrating | #2579 |
| mannwhitney | #2580 |
| vcam1 | #2583 |
| tonometry ocular | #2587 |
| aged myopia | #2593 |
| excimer laser | #2597 |
| methods subjects | #2602 |
| fibroblasts humans | #2610 |
| subjects 12 | #2614 |
| complications adolescent | #2619 |
| baseline treatment | #2620 |
| contact lens | #2624 |
| eosinophilia female | #2629 |
| postsurgical | #2629 |
| 6 months treatment | #2638 |
| lamp | #2646 |
| cyclosporine drug | #2647 |
| cyclosporine csa | #2653 |
| alpha adolescent | #2655 |
| 412 | #2656 |
| administered day | #2664 |
| rantes | #2665 |
| mucins | #2672 |
| cataract extraction | #2683 |
| symptom score | #2687 |
| infections respiratory | #2694 |
| groups differences | #2695 |
| bf | #2698 |
| tearing | #2698 |
| chemokine ccl5 | #2712 |
| studies glucocorticoids | #2717 |
| control eyes | #2721 |
| muc1 | #2726 |
| fibroblasts gene | #2731 |
| alpha vascular | #2735 |
| chemokine production | #2739 |
| hne | #2743 |
| factors chemotaxis | #2746 |
| laser scanning | #2747 |
| tomography oct | #2754 |
| immunocytochemical staining | #2759 |
| betamethasone | #2761 |
| matched normal | #2772 |
| total ige | #2772 |
| atopic female | #2773 |
| chronic graft | #2786 |
| humans immunoenzyme | #2792 |
| symptomatic improvement | #2794 |
| prevention adolescent | #2797 |
| male adolescent | #2813 |
| iop | #2817 |
| scores lower | #2818 |
| whitney | #2819 |
| atopic dermatitis | #2821 |
| higher cases | #2821 |
| dry | #2840 |
| groups normal | #2842 |
| analog scale | #2845 |
| aminobenzoates | #2846 |
| months surgery | #2850 |
| crystalline lens | #2855 |
| treatment 4 | #2868 |
| fibroblasts fibronectins | #2889 |
| qol scores | #2892 |
| syndrome patients | #2902 |
| evaporation rate | #2903 |
| mannwhitney test | #2905 |
| test performed | #2907 |
| anterior chamber | #2907 |
| il1beta | #2910 |
| tests diagnosis | #2922 |
| postoperative follow | #2926 |
| drop | #2927 |
| cgvhd | #2929 |
| surgery 2 | #2932 |
| eye diseases | #2940 |
| interleukin8 il8 | #2953 |
| endophthalmitis | #2955 |
| refraction ocular | #2961 |
| excision | #2987 |
| inter rater | #3000 |
| measured elisa | #3014 |
| eosinophils humans | #3014 |
| normal eyes | #3037 |
| cultured chemokines | #3051 |
| agents interferon | #3054 |
| protease activated | #3059 |
| staining labeling | #3068 |
| safety assessed | #3072 |
| evaporation | #3080 |
| aged anti | #3083 |
| treatment total | #3085 |
| immunologic receptors | #3118 |
| baseline month | #3124 |
| expression adhesion | #3132 |
| rtpcr | #3132 |
| dermatitis | #3150 |
| vehicle | #3153 |
| cells graft | #3163 |
| susceptibility humans | #3175 |
| cell count | #3181 |
| symptom scores | #3181 |
| methods seventy | #3188 |
| 10 patients | #3190 |
| investigate efficacy | #3197 |
| recruited study | #3208 |
| sjogren syndrome | #3228 |
| study medication | #3240 |
| patient global | #3249 |
| cell densities | #3269 |
| accommodation | #3274 |
| acuity | #3280 |
| meniscus | #3289 |
| variance case | #3295 |
| interferometry | #3299 |
| normal control subjects | #3302 |
| intraoperative male | #3322 |
| allergens | #3325 |
| cells assessed | #3332 |
| subjective | #3340 |
| efficacy anti | #3343 |
| diclofenac sodium | #3345 |
| dressings | #3352 |
| histamine receptor | #3356 |
| cellular level | #3367 |
| pfu | #3369 |
| diabetic patients | #3375 |
| fibroblast proliferation | #3377 |
| coherence tomography | #3398 |
| ova | #3409 |
| instillation | #3411 |
| normal subjects | #3415 |
| air pollutants | #3416 |
| alpha cell | #3440 |
| patients obstructive | #3460 |
| host disease humans | #3469 |
| papilla | #3493 |
| cataract | #3514 |
| local excision | #3555 |
| interleukin8 male | #3570 |
| visual analog | #3572 |
| agents steroidal | #3585 |
| sjogren | #3591 |
| tokyo | #3609 |
| immunoglobulin ige | #3614 |
| signs | #3617 |
| agents incidence | #3623 |
| plaque formation | #3626 |
| weeks surgery | #3640 |
| method enzyme | #3648 |
| pressure male | #3653 |
| cell density | #3654 |
| fiftytwo patients | #3661 |
| adult chronic | #3668 |
| disease adolescent | #3694 |
| vegf mrna | #3694 |
| 016 ± | #3698 |
| cytological | #3709 |
| 29 years | #3711 |
| gels humans | #3720 |
| week 1 | #3745 |
| suture techniques | #3751 |
| adult air | #3751 |
| signs symptoms | #3758 |
| pm25 | #3770 |
| situ nickend | #3772 |
| helper type | #3773 |
| management disease | #3773 |
| anterior segment | #3782 |
| hydrochloride | #3792 |
| lenses | #3815 |
| docosahexaenoic acid dha | #3823 |
| perennial | #3824 |
| patients examined | #3835 |
| amniotic | #3843 |
| studies severity | #3851 |
| intercellular adhesion molecule | #3865 |
| interleukin13 | #3866 |
| strabismus | #3900 |
| diseases study | #3906 |
| complications observed | #3914 |
| mann | #3916 |
| interleukin2 interleukin4 | #3949 |
| specific ige | #3951 |
| subjects included | #3968 |
| cell expression | #3989 |
| chemokines | #3992 |
| microscopy | #3992 |
| discontinued treatment | #3993 |
| break | #3994 |
| lower compared | #3996 |
| studies roc | #3998 |
| ulcer | #4009 |
| cells hla | #4035 |
| female flow | #4036 |
| echinocandins | #4040 |
| acrylic resins | #4047 |
| immunosuppressive | #4068 |
| readings | #4071 |
| steroid | #4091 |
| subjects methods | #4093 |
| steroid treatment | #4095 |
| acinar | #4097 |
| discontinue | #4100 |
| inflammatory disorders | #4103 |
| tended higher | #4106 |
| ige | #4116 |
| bronchial asthma | #4135 |
| th2 | #4137 |
| severe effects | #4168 |
| female glaucoma | #4179 |
| aged sensitivity | #4189 |
| papillary | #4193 |
| α induced | #4193 |
| male surveys | #4211 |
| measured enzyme | #4218 |
| percentages | #4223 |
| visual acuity | #4239 |
| gamma interleukin1 | #4281 |
| heidelberg | #4286 |
| adult antibody | #4327 |
| purpose report | #4328 |
| clinically diagnosed | #4349 |
| visual function | #4360 |
| edema | #4368 |
| effective improving | #4382 |
| 11 patients | #4410 |
| reaction rna | #4417 |
| infiltrates | #4459 |
| interleukin | #4482 |
| healed | #4489 |
| conclusions clinical | #4503 |
| studies environmental | #4513 |
| scores | #4515 |
| gamma interleukin4 | #4530 |
| 14 28 | #4549 |
| baseline 2 | #4575 |
| excimer | #4592 |
| viral respiratory | #4601 |
| surface reconstruction | #4608 |
| blinding | #4654 |
| years recruited | #4660 |
| lid | #4671 |
| cytometric | #4683 |
| studies prosthesis | #4704 |
| patients bilateral | #4711 |
| chemotactic | #4713 |
| treatment conclusions | #4714 |
| 4 9 | #4720 |
| tomography optical | #4729 |
| immunoenzyme | #4748 |
| dermatitis contact | #4754 |
| 36 years | #4755 |
| 80 child | #4790 |
| glaucoma patients | #4793 |
| purpose assess | #4807 |
| healthy control subjects | #4826 |
| patients administration | #4833 |
| 111 patients | #4837 |
| immunoenzyme techniques | #4857 |
| protein array | #4864 |
| allergy | #4868 |
| fluoresceins fluorescent | #4892 |
| adult biological | #4902 |
| chronic gvhd | #4913 |
| foreign body | #4922 |
| defensins | #4929 |
| infrared rays | #4946 |
| scale 0 | #4948 |
| logarithm | #4974 |
| lower density | #5019 |
| nitrogen dioxide | #5023 |
| months treatment | #5023 |
| optical coherence | #5029 |
| groups compared | #5036 |
| opacities | #5052 |
| enterotoxins | #5054 |
| safety treatment | #5056 |
| unpaired | #5095 |
| amnion | #5097 |
| induced male | #5101 |
| strip | #5103 |
| lipopeptides | #5119 |
| glaucoma | #5131 |
| purposewe | #5143 |
| receptors chemokine | #5174 |
| patients 100 | #5189 |
| steroids | #5194 |
| thirtysix patients | #5224 |
| epithelium | #5224 |
| observed 2 | #5246 |
| determine efficacy | #5268 |
| lysine male | #5269 |
| child combined | #5301 |
| analysis reverse | #5302 |
| 2 weeks | #5303 |
| enzyme linked | #5314 |
| time measurements | #5318 |
| 74 years | #5320 |
| humans hyperthermia | #5365 |
| imidazoles male | #5366 |
| 20 25 | #5367 |
| allergen | #5403 |
| metaplasia | #5404 |
| agents chronic | #5423 |
| factors visual | #5431 |
| procedures postoperative | #5475 |
| differential disease | #5487 |
| igg anti | #5508 |
| keratitis | #5509 |
| alum | #5527 |
| mucin1 | #5530 |
| treatment follow | #5537 |
| barr virus | #5547 |
| humans lasers | #5560 |
| epithelial barrier | #5584 |
| counted | #5606 |
| visual analog scale | #5621 |
| spearman correlation | #5634 |
| aims evaluate | #5656 |
| giant | #5659 |
| publication administration | #5662 |
| il13 | #5676 |
| sutures | #5684 |
| eye proteins | #5692 |
| opacity | #5697 |
| histamine antagonists | #5721 |
| tonometry | #5735 |
| techniques cells | #5746 |
| grades | #5747 |
| th2 cells | #5747 |
| adult cell | #5754 |
| 889 | #5801 |
| male time | #5839 |
| tgfbeta1 | #5853 |
| sickness impact | #5861 |
| icam1 | #5871 |
| agents candida | #5881 |
| score 3 | #5903 |
| biomarkers case | #5924 |
| expression alpha | #5963 |
| nsaid | #5969 |
| antibody anti | #5999 |
| microscopy study | #6002 |
| chemotactic factors | #6005 |
| ip10 | #6027 |
| adverse health effects | #6035 |
| rhinitis allergic | #6041 |
| humans hyaluronic | #6046 |
| higher compared | #6074 |
| exacerbate | #6114 |
| controlled clinical | #6123 |
| baseline 1 | #6145 |
| placebo treatment | #6146 |
| thickening | #6158 |
| male neutrophils | #6171 |
| patients refractory | #6181 |
| treatment adverse | #6199 |
| desiccation | #6204 |
| resultsthe | #6224 |
| genetic adolescent | #6226 |
| diagnostic techniques | #6234 |
| efficacy | #6247 |
| impact profile | #6258 |
| subjects randomized | #6267 |
| johnson | #6274 |
| steroidal | #6295 |
| cells lymphocytes | #6296 |
| patients control | #6337 |
| dosed | #6343 |
| allergies | #6348 |
| ocular hypertension | #6376 |
| 005 conclusion | #6428 |
| ulceration | #6435 |
| japan male | #6443 |
| asthmatic agents | #6445 |
| wearing | #6466 |
| 2 groups | #6475 |
| air pollution | #6514 |
| house dust | #6543 |
| rejection humans | #6543 |
| primary human | #6559 |
| diclofenac | #6566 |
| 3 groups | #6582 |
| anti asthmatic | #6611 |
| glucocorticoids humans | #6618 |
| linked immunosorbent | #6618 |
| 3 months | #6643 |
| conventional therapy | #6652 |
| immunosorbent assay | #6675 |
| months compared | #6704 |
| humans japan | #6704 |
| inflammatory | #6764 |
| chemokine | #6774 |
| graded | #6779 |
| breakup | #6780 |
| severe | #6799 |
| serum total | #6811 |
| 1 14 | #6842 |
| male microscopy | #6859 |
| treatment refractory | #6864 |
| bcva | #6877 |
| enzymelinked immunosorbent assay | #6904 |
| conventional treatment | #6981 |
| wear | #7013 |
| adhesion molecules | #7016 |
| years treated | #7049 |
| contrast sensitivity | #7060 |
| observed treatment | #7063 |
| humans hypothermia | #7079 |
| 6 patients | #7102 |
| epsteinbarr virus | #7188 |
| transplantation child | #7270 |
| patients 9 | #7284 |
| water loss | #7310 |
| infections herpesvirus | #7328 |
| viral female | #7329 |
| treatment period | #7342 |
| syndromes | #7375 |
| photography | #7394 |
| severity | #7473 |
| relief | #7481 |
| seasonal | #7483 |
| alpha regulation | #7520 |
| confocal microscopy | #7575 |
| epithelial | #7618 |
| humans immunoglobulin | #7674 |
| inflammatory agents | #7677 |
| autumn | #7680 |
| treatment decreased | #7714 |
| calcineurin inhibitors | #7727 |
| 16 patients | #7794 |
| hyperthermia induced | #7892 |
| cyclosporine | #7933 |
| epstein barr | #8024 |
| steroidal anti | #8072 |
| tnfalpha | #8140 |
| methods fifty | #8160 |
| fk506 | #8206 |
| aged minimally | #8301 |
| barr | #8314 |
| production human | #8367 |
| assess safety | #8419 |
| evaluate effectiveness | #8448 |
| purpose | #8455 |
| patients normal | #8497 |
| regulation vascular | #8551 |
| statistically differences | #8556 |
| hypothermia induced | #8648 |
| graft rejection | #8670 |
| hladr | #8682 |
| corticosteroid | #8683 |
| epithelial cells | #8827 |
| score 1 | #8860 |
| design prospective | #8861 |
| year male | #8873 |
| ceramides | #8893 |
| capsular | #8909 |
| ovalbumin | #8972 |
| silicone | #8991 |
| anti inflammatory | #9041 |
| surgical flaps | #9087 |
| 3 6 | #9098 |
| complaints | #9098 |
| illness adolescent | #9141 |
| immunosorbent | #9162 |
| humidity | #9176 |
| cutoff values | #9181 |
| patients 16 | #9191 |
| 4 12 | #9193 |
| treatment adolescent | #9195 |
| 0 3 | #9331 |
| wilcoxon | #9408 |
| 375 | #9414 |
| virus ebv | #9435 |
| 8 patients | #9463 |
| humans intraoperative | #9556 |
| hypersensitivity | #9569 |
| reaction tumor | #9638 |
| adult anti | #9709 |
| particulate matter | #9803 |
| superficial | #9826 |
| refraction | #9835 |
| methods prospective | #9836 |
| anesthetics local | #9840 |
| limbic | #9855 |
| fluorescent dyes | #9935 |
| term treatment | #10001 |
| objectively | #10055 |
| postoperatively | #10097 |
| technique indirect | #10132 |
| symptoms patients | #10143 |
| 1year followup | #10154 |
| 10 minutes | #10161 |
| foreign | #10171 |
| factor vegf | #10178 |
| biomarkers child | #10229 |
| antigens humans | #10284 |
| compared treatment | #10317 |
| rhinitis | #10337 |
| glands | #10364 |
| cytokines | #10378 |
| week 4 | #10414 |
| common complication | #10417 |
| questionnaire | #10420 |
| shortterm | #10427 |
| mast cells | #10496 |
| lens | #10588 |
| subjects age | #10599 |
| longterm treatment | #10644 |
| chamber | #10647 |
| male prospective | #10703 |
| volunteers | #10707 |
| substance | #10715 |
| compared controls | #10729 |
| nsaids | #10777 |
| cells th2 | #10778 |
| filtering | #10900 |
| metabolism male | #10953 |
| il5 | #11022 |
| examinations | #11187 |
| patient demographics | #11192 |
| 20 40 | #11212 |
| body temperature | #11219 |
| complications retrospective | #11251 |
| eczema | #11287 |
| patients 4 | #11337 |
| purposeto | #11381 |
| nonsteroidal | #11393 |
| corrected | #11394 |
| mast | #11549 |
| interleukin8 | #11599 |
| eosinophilic | #11723 |
| adjunctive | #11730 |
| receptors immunologic | #11956 |
| longterm outcomes | #12069 |
| evaluate | #12086 |
| grading | #12107 |
| coherence | #12125 |
| prospective | #12163 |
| 0001 conclusions | #12216 |
| csa | #12259 |
| asthmatic | #12282 |
| sickness | #12312 |
| tnf α | #12395 |
| thirty | #12576 |
| volunteers humans | #12586 |
| evaluate effects | #12612 |
| elisa | #12717 |
| mucous | #12766 |
| tnfα | #12781 |
| agents anti | #12822 |
| evaluate safety | #12879 |
| host disease | #12922 |
| seconds | #13199 |
| minutes | #13216 |
| complications diabetes | #13262 |
| epithelia | #13267 |
| 4 weeks | #13267 |
| 005 | #13326 |
| tests performed | #13356 |
| 1 3 | #13413 |
| 2 cases | #13447 |
| underwent | #13549 |
| western blot analysis | #13578 |
| prosthesis design | #13600 |
| cultured coculture | #13613 |
| particulate | #13632 |
| clinical examination | #13829 |
| life surveys | #13937 |
| mast cell | #13997 |
| study clinical | #14017 |
| dogs female | #14046 |
| graft host | #14084 |
| 60 patients | #14391 |
| myopia | #14577 |
| diseases diabetes | #14729 |
| vascular cell | #14846 |
| spearman | #14877 |
| implantation | #14889 |
| infections staphylococcus | #15065 |
| hyaluronic | #15111 |
| allograft | #15158 |
| patients follow | #15344 |
| visual | #15382 |
| refractory | #15389 |
| burning | #15485 |
| discontinued | #15495 |
| 1 2 | #15658 |
| longterm | #15717 |
| 006 | #15839 |
| graft | #15913 |
| tnf alpha | #16084 |
| radiation injuries | #16251 |
| patients divided | #16456 |
| 32 patients | #16659 |
| 15 patients | #16684 |
| adhesion molecule1 | #16940 |
| herpesvirus 4 | #16966 |
| evaluate efficacy | #17035 |
| 4 human | #17084 |
| patients assigned | #17274 |
| noninvasive | #17324 |
| molecule1 | #17435 |
| antibiotics antineoplastic | #17587 |
| histopathologic | #17743 |
| acid male | #17891 |
| method female | #17912 |
| anterior | #17986 |
| symptoms | #18008 |
| inflammation | #18029 |
| healthy | #18209 |
| morphologic | #18280 |
| stained | #18391 |
| alkylating | #18391 |
| vegf | #18469 |
| 0001 | #18534 |
| cold temperature | #18622 |
| 00001 | #18681 |
| 9 patients | #18689 |
| neovascularization | #19381 |
| female fluorescent | #19461 |
| stromal | #19499 |
| aged postoperative | #19510 |
| lipids male | #19666 |
| endothelial growth | #19723 |
| nerve fibers | #19872 |
| follow period | #19917 |
| artificial | #20012 |
| female graft | #20067 |
| 24 patients | #20143 |
| count cell | #20148 |
| epithelial cell | #20437 |
| complications prospective | #20558 |
| patients evaluated | #20800 |
| 22 patients | #21524 |
| 003 | #21648 |
| daily | #22391 |
| gland | #22647 |
| followup period | #22674 |
| male middle aged | #22802 |
| ifngamma | #23824 |
| outcome measures | #24510 |
| enrolled | #24838 |
| transplantation homologous | #25557 |
| patients adolescent | #25760 |
| adult body | #25783 |
| adult analysis | #26261 |
| conclusions patients | #26516 |
| adult biomarkers | #29382 |
| statistically | #29861 |
| age matched | #29948 |
| humans inflammation | #30660 |
| cells female | #31500 |
Rapport d'exécution | |
Prominent publications by Hiroshi Fujishima
KOL-Index: 19369
PURPOSE: To describe MUC5AC alterations and the ocular surface disorder in atopic patients with or without corneal ulcers.
METHODS: Atopic patients' eyes were divided into two groups according to the presence and absence of corneal ulceration. The subjects underwent corneal sensitivity measurements, Schirmer test, tear film break-up time (BUT), fluorescein and Rose Bengal staining of the ocular surface and conjunctival impression cytology and brush cytology. Impression cytology samples ...
| Connu pour Ocular Surface | Eyes Corneal Ulcers | Atopic Patients | Brush Cytology | Akc Vkc |
Application of Visante Optical Coherence Tomography Tear Meniscus Height Measurement in the Diagnosis of Dry Eye Disease
[ PUBLICATION ]
PURPOSE: To investigate the applicability of tear meniscus height (TMH) measurement using Visante optical coherence tomography (OCT) in the diagnosis of dry eye disease.
DESIGN: Prospective, controlled, single-center study.
PARTICIPANTS: Twenty-four right eyes of 24 patients (6 males, 18 females; mean age, 63.14±13.4 years) with definite dry eye according to the Japanese dry eye diagnostic criteria and 27 right eyes of 27 control subjects (12 males, 15 females; mean age, 56.04±14.22 ...
| Connu pour Dry Eye Disease | Coherence Tomography | Tear Meniscus Height | Sensitivity Specificity | Strip Meniscometry |
Evaluation of lipid oxidative stress status and inflammation in atopic ocular surface disease.
[ PUBLICATION ]
BACKGROUND: Although the oxidative stress status in atopic skin disease has been reported to be elevated, there are still no studies related to the status of oxidative stress in atopic ocular surface disease. The purpose of this study was to evaluate the ocular surface lipid oxidative stress status and inflammation in atopic keratoconjunctivitis (AKC) patients and normal subjects.
METHODS: Twenty eight eyes of 14 patients (9 males, 5 females) with AKC and 18 eyes of 9 age and sex matched ...
| Connu pour Oxidative Stress | Akc Patients | Surface Disease | Inflammatory Cells | 5 Females |
KOL-Index: 11411
PURPOSE: To evaluate the effectiveness and safety of a novel cyclosporine 0.1% aqueous ophthalmic solution in a large population with vernal keratoconjunctivitis (VKC) and atopic keratoconjunctivitis (AKC).
METHODS: A prospective observational postmarketing study was initiated in Japan. A total of 594 patients with VKC or AKC were started on this drug within 1 year after market launch (January 2006) and completed a 6-month follow-up. These patients were observed clinically, and ...
| Connu pour Vkc Akc | Allergic Conjunctivitis | Topical Steroids | 1 Month | Objective Signs |
Alterations of the ocular surface epithelial MUC16 and goblet cell MUC5AC in patients with atopic keratoconjunctivitis
[ PUBLICATION ]
BACKGROUND: An increased understanding of the ocular surface at cellular level in the conjunctiva and the cornea may help explain the pathogenesis and the subsequent clinical appearance of atopic ocular allergies, which may be potentially blinding.
PURPOSE: To investigate the MUC16 and MUC5AC alterations, tear function and the ocular surface disorder in patients with atopic keratoconjunctivitis (AKC).
METHODS: Thirty-six eyes of 18 AKC patients as well as 28 eyes of 14 age- and ...
| Connu pour Atopic Keratoconjunctivitis | Ocular Surface | Patients Akc | Muc5ac Muc16 | Goblet Cell |
KOL-Index: 10572
BACKGROUND: The pathogenesis of the ocular surface disease in atopic keratoconjunctivitis (AKC) and vernal keratoconjunctivitis (VKC) has not been fully understood. We tried to clarify the differences in the ocular surface status in patients with AKC, VKC, and healthy control subjects.
METHODS: Twenty-four eyes of 12 AKC patients, 12 eyes of six VKC patients, and 20 eyes of 10 normal control subjects were studied. The subjects underwent corneal sensitivity measurements, Schirmer test, ...
| Connu pour Ocular Surface | Atopic Keratoconjunctivitis | Patients Akc | Eyes Vkc | Brush Cytology |
Alterations of the ocular surface epithelial mucins 1, 2, 4 and the tear functions in patients with atopic keratoconjunctivitis
[ PUBLICATION ]
BACKGROUND: An increased understanding of the ocular surface alterations at the cellular level in the conjunctiva and the cornea, may help explain the pathogenesis and the subsequent clinical appearance of atopic ocular allergies, which may be potentially blinding.
PURPOSE: To investigate MUC 1, 2 and 4 alterations, tear function and the ocular surface disorder in patients with atopic keratoconjunctivitis.
METHODS: Twenty-eight eyes of 14 atopic keratoconjunctivitis patients as well as ...
| Connu pour Atopic Keratoconjunctivitis | Ocular Surface | Brush Cytology | Corneal Sensitivity | Epithelial Mucins |
KOL-Index: 10372
PURPOSE: To prospectively assess the clinical outcome after implantation of the 1CU accommodating intraocular lens (IOL) and a foldable acrylic IOL (AcrySof, Alcon).
SETTING: Department of Ophthalmology, Tokyo Dental College, Ichikawa Hospital, Ichikawa, and Minami Aoyama Eye Clinics, Tokyo, Yokohama, Japan.
METHODS: Twenty-two eyes of 16 patients with cataract had phacoemulsification implantation of 1CU accommodating IOL. Twenty eyes of 10 age-matched and sex-matched patients with ...
| Connu pour Intraocular Lens | Visual Acuity | 1cu Iol | Cataract Surgery | Amplitude Accommodation |
KOL-Index: 10324
PURPOSE: Eosinophils are known to have important roles in the pathogenesis of allergic conjunctivitis. Prostaglandin (PG) D2, which has been implicated as a factor in allergic diseases, is known to have chemotactic activity for eosinophils. Its receptor, chemoattractant receptor homologous molecule expressed on TH2 (CRTH2), serves as a receptor for PGD2 and has been reported to mediate PGD2-dependent migration of eosinophils. In the present study, both eosinophil toxic activity for ...
| Connu pour Receptor Crth2 | Chemotaxis Eosinophils | Allergic Conjunctivitis | Pgd2dependent Migration | Homologous Molecule |
A Randomized, Placebo-Controlled Clinical Trial of Tacrolimus Ophthalmic Suspension 0.1% in Severe Allergic Conjunctivitis
[ PUBLICATION ]
AIMS: To examine the efficacy of tacrolimus ophthalmic suspension 0.1% in treating severe allergic conjunctivitis.
METHODS: This was a multicenter, randomized, double-masked, placebo-controlled clinical trial. Fifty-six patients with severe allergic conjunctivitis in whom topical antiallergic agents and corticosteroids had been ineffective were randomized to tacrolimus or placebo treatment. Patients were treated either with tacrolimus or placebo twice-daily for 4 weeks. Severity of ...
| Connu pour Severe Allergic Conjunctivitis | Tacrolimus Ophthalmic | Objective Signs | Corneal Involvement | Clinical Trial |
TGF-beta1, IL-1beta, and Th2 cytokines stimulate vascular endothelial growth factor production from conjunctival fibroblasts
[ PUBLICATION ]
Giant papillary formation containing newly formed vessels is a major characteristic of severe allergic conjunctivitis, such as atopic keratoconjunctivitis (AKC) or vernal keratoconjunctivitis (VKC). We examined production of vascular endothelial growth factor (VEGF) from cultured conjunctival fibroblasts from normal volunteers under stimulation with type 1-, type 2-helper T cell derived and proinflammatory cytokines to investigate the mechanism of giant papillae formation in AKC/VKC. ...
| Connu pour Conjunctival Fibroblasts | Vascular Endothelial | Growth Factor | Vegf Concentration | Akc Vkc |
KOL-Index: 9650
PURPOSE: To prospectively assess the clinical and visual outcomes of phacoemulsification and implantation of a rollable intraocular lens (IOL) with a thin optic and compare the results with those of implantation of a foldable acrylic IOL.
SETTING: Department of Ophthalmology, Tokyo Dental College, Ichikawa General Hospital, Ichikawa, Chiba, Japan.
METHODS: Sixteen consecutive eyes of 8 patients (4 women, 4 men) with corticonuclear cataract had small-incision clear corneal ...
| Connu pour Intraocular Lens | Thinoptx Iol | Phacoemulsification Implantation | Visual Acuity | 6 Months |
Ocular surface and tear functions after topical cyclosporine treatment in dry eye patients with chronic graft-versus-host disease
[ PUBLICATION ]
We investigated the effect of 0.05% topical cyclosporine (Cys) on the ocular surface and tear functions in dry eye patients with chronic GVHD (cGVHD) in a prospective comparative study. Thirty eyes of 15 patients refractory to baseline treatment were recruited and the patients assigned for topical Cys treatment group (14 eyes of 7 patients) and control group (12 eyes of 6 patients) respectively. Two patients dropped out because of intolerable irritation while using topical Cys eye drops. ...
| Connu pour Ocular Surface | Topical Cyclosporine | Eye Patients | Chronic Graft | Host Disease |
Measurement of IL‐4 in tears of patients with seasonal allergic conjunctivitis and vernal keratoconjunctivitis
[ PUBLICATION ]
To elucidate the mechanism of ocular surface allergic disease, we focused on IL-4, which is one of the key factors in regulating IgE production, and thus determined the concentration of IL-4 in tears. IL-4 concentration was determined in the tears of 15 patients with seasonal allergic conjunctivitis, 15 vernal keratoconjunctivitis (VKC), 10 giant papillary conjunctivitis (GPC), 10 patients with non-allergic conjunctivitis and post-cataract surgical conjunctivitis as intermediate ...
| Connu pour Allergic Conjunctivitis | Tears Patients | Vkc Gpc | Normal Controls | Linked Immunosorbent |
Des personnes clés pour Allergic Conjunctivitis
Top Kols dans le monde
Sélectionnez une phrase de recherche allergic conjunctivitis , allergic conjunctivitis asthma , allergic conjunctivitis mice , allergic conjunctivitis children , allergic conjunctivitis patients
Hiroshi Fujishima:Impact expert
Concepts pour lesquelsHiroshi Fujishimaa une influence directe:Allergic conjunctivitis, Dry eye, Atopic keratoconjunctivitis, Conjunctival fibroblasts, Allergic conjunctival disease, Brush cytology, Ocular surface, Vernal keratoconjunctivitis.
Hiroshi Fujishima:Impact de Kol
Concepts liés au travail d'autres auteurs pour lesquelsfor which Hiroshi Fujishima a une influence:Dry eye, Ocular surface, Allergic conjunctivitis, Tear film, Amniotic membrane, Cataract surgery, Contact lens.
Tools
Est-ce votre profil? Réclamez votre profil Copier le lien ENCHED LIEN À VOTRE PROFIL |